CA2989161C - Ethynylxanthines, preparation and use for cancer treatment - Google Patents
Ethynylxanthines, preparation and use for cancer treatment Download PDFInfo
- Publication number
- CA2989161C CA2989161C CA2989161A CA2989161A CA2989161C CA 2989161 C CA2989161 C CA 2989161C CA 2989161 A CA2989161 A CA 2989161A CA 2989161 A CA2989161 A CA 2989161A CA 2989161 C CA2989161 C CA 2989161C
- Authority
- CA
- Canada
- Prior art keywords
- 4alkyl
- purine
- 3alkyl
- amino
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 20
- 201000011510 cancer Diseases 0.000 title abstract description 20
- 238000002360 preparation method Methods 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 62
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 54
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 12
- -1 5-oxohexyl Chemical group 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 229910052757 nitrogen Chemical group 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000011593 sulfur Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 5
- 201000008274 breast adenocarcinoma Diseases 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 150000004677 hydrates Chemical class 0.000 claims description 5
- GSNUFIFRDBKVIE-UHFFFAOYSA-N 2,5-dimethylfuran Chemical compound CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 125000003725 azepanyl group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 5
- 101150041968 CDC13 gene Proteins 0.000 description 35
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 34
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 13
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- CEBKHWWANWSNTI-UHFFFAOYSA-N 2-methylbut-3-yn-2-ol Chemical compound CC(C)(O)C#C CEBKHWWANWSNTI-UHFFFAOYSA-N 0.000 description 10
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 10
- 229960001948 caffeine Drugs 0.000 description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- RTJJUSOTMOJOBF-UHFFFAOYSA-N 8-ethynyl-3,7-dihydropurine-2,6-dione Chemical class O=C1NC(=O)NC2=C1NC(C#C)=N2 RTJJUSOTMOJOBF-UHFFFAOYSA-N 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 5
- 229910021120 PdC12 Inorganic materials 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- 229960001476 pentoxifylline Drugs 0.000 description 5
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940061353 temodar Drugs 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- ZFQWSCZYQLPFFZ-UHFFFAOYSA-N 8-bromo-3,7-dihydropurine-2,6-dione Chemical group N1C(=O)NC(=O)C2=C1N=C(Br)N2 ZFQWSCZYQLPFFZ-UHFFFAOYSA-N 0.000 description 3
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 210000001196 cardiac muscle myoblast Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VVSASNKOFCZVES-UHFFFAOYSA-N 1,3-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound CN1C(=O)CC(=O)N(C)C1=O VVSASNKOFCZVES-UHFFFAOYSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- 101150051188 Adora2a gene Proteins 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- BZILLIQIFXIRND-UHFFFAOYSA-N 7-benzyl-8-ethynyl-3H-purine-2,6-dione Chemical class C(C1=CC=CC=C1)N1C(=NC=2NC(NC(C1=2)=O)=O)C#C BZILLIQIFXIRND-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LIYPIYBPJXKPIV-UHFFFAOYSA-N 8-[3-(dimethylamino)propoxy]-1,3,7-trimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=C(OCCCN(C)C)N2C LIYPIYBPJXKPIV-UHFFFAOYSA-N 0.000 description 1
- YRLRORFORQUTKS-UHFFFAOYSA-N 8-bromo-1,3,7-trimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=C(Br)N2C YRLRORFORQUTKS-UHFFFAOYSA-N 0.000 description 1
- OWNQGBIVMSHGRQ-UHFFFAOYSA-N 8-ethynyl-1,3,7-trimethylpurine-2,6-dione Chemical class C(#C)C1=NC=2N(C(N(C)C(C=2N1C)=O)=O)C OWNQGBIVMSHGRQ-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000615866 Antho Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100031772 Short transient receptor potential channel 5 Human genes 0.000 description 1
- 101710173825 Short transient receptor potential channel 5 Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000000801 calcium channel stimulating agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to ethynylxanthine derivatives of formula (l) which exhibit high antiproliferative activity against various tumour cell lines, methods for their synthesis and use for the treatment and/or prevention of cancer.
Description
ETHYNYLXANTHINES, PREPARATION AND USE FOR CANCER
TREATMENT
FIELD OF THE INVENTION
The present invention relates to novel ethynylxanthine derivatives, methods for their synthesis and use for the treatment and/or prevention of cancer.
BACKGROUND OF THE INVENTION
Cancer is one of the main causes of death among economically developed countries (Jermal, CA Cancer J. Clin., 2011, 61 69-90). According to the International Health Organization, more than 7 million people diagnosed with various forms of cancer, die each year (Jermal, CA Cancer J. Clin., 2010, 60, 277-300; Siegel, CA Cancer J.
Clin.
2012, 62, 10-29). Unfortunately, the number of cancer diagnosis in past few years has increased almost twice. In clinical practice, the treatment of cancer involves a wide range of chemotherapy drugs. Besides, most of them exhibit various side effects, high toxicity and moderate selectivity. Therefore, a new generation of selective, low toxic anticancer agent development is one of the main tasks in medicinal chemistry and pharmaceutical industries. Despite the advanced studies in the elaboration of anticancer drugs, the treatment outcome for brain malignant tumors still remains a challenge. The majority of promising antitumor drugs used against brain tumors in clinical trials, unfortunately, had limited impact on human survival, due to inadequacy of efficient drug delivery to the target in the central nervous system (CNS) at a sufficient concentration (Siegal, Neuro Oncol., 2013 10.1093/neuonc/not016;
Lampson, Drug Discov. Today, 2009, 14, 185-191; Huse, Nat. Rev., 2010, 10, 319-331).
Increased interest in xanthines stems from the fact that this heterocyclic system occurs in a number of natural substances; xanthine derivatives are able to cross through the blood brain barrier (BBB). It is an important class of compounds with a wide range of pharmacological effects, including anticancer, anti-HIV, anticoagulant, antispasmodic and antibacterial activity. Nowadays, in clinical practice, a number of anticancer drugs based on the structure of the natural purine analogues were developed (cladribine, fludarabine, mercaptopurine, thioguanine, clofarabine, nelarabine, etc.).
These are the first line therapy agents to cure hematologic malignant diseases. Agents Date Recue/Date Received 2021-07-07
TREATMENT
FIELD OF THE INVENTION
The present invention relates to novel ethynylxanthine derivatives, methods for their synthesis and use for the treatment and/or prevention of cancer.
BACKGROUND OF THE INVENTION
Cancer is one of the main causes of death among economically developed countries (Jermal, CA Cancer J. Clin., 2011, 61 69-90). According to the International Health Organization, more than 7 million people diagnosed with various forms of cancer, die each year (Jermal, CA Cancer J. Clin., 2010, 60, 277-300; Siegel, CA Cancer J.
Clin.
2012, 62, 10-29). Unfortunately, the number of cancer diagnosis in past few years has increased almost twice. In clinical practice, the treatment of cancer involves a wide range of chemotherapy drugs. Besides, most of them exhibit various side effects, high toxicity and moderate selectivity. Therefore, a new generation of selective, low toxic anticancer agent development is one of the main tasks in medicinal chemistry and pharmaceutical industries. Despite the advanced studies in the elaboration of anticancer drugs, the treatment outcome for brain malignant tumors still remains a challenge. The majority of promising antitumor drugs used against brain tumors in clinical trials, unfortunately, had limited impact on human survival, due to inadequacy of efficient drug delivery to the target in the central nervous system (CNS) at a sufficient concentration (Siegal, Neuro Oncol., 2013 10.1093/neuonc/not016;
Lampson, Drug Discov. Today, 2009, 14, 185-191; Huse, Nat. Rev., 2010, 10, 319-331).
Increased interest in xanthines stems from the fact that this heterocyclic system occurs in a number of natural substances; xanthine derivatives are able to cross through the blood brain barrier (BBB). It is an important class of compounds with a wide range of pharmacological effects, including anticancer, anti-HIV, anticoagulant, antispasmodic and antibacterial activity. Nowadays, in clinical practice, a number of anticancer drugs based on the structure of the natural purine analogues were developed (cladribine, fludarabine, mercaptopurine, thioguanine, clofarabine, nelarabine, etc.).
These are the first line therapy agents to cure hematologic malignant diseases. Agents Date Recue/Date Received 2021-07-07
2 in the therapeutic effect of complete remission constitute 80% after monochemotherapy course. Such compounds act as antimetabolites by replacing the natural nucleoside in DNA and RNA synthesis such as multi-cellular enzyme inhibitors. Unfortunately, these drugs showed a wide range of side effects, and high treatment costs limit the possibilities in clinical practice.
To minimize side effects currently being developed antitumor drugs based on caffeine core. Caffeine derivatives possess CNS expression as calcium agonist or antagonist effect. Recent studies show that caffeine-containing coffee daily use is able to lower mouth and brain cancer formation up to 39% (Michaud, Am. J. Clin. Nutr. 2010, 92, 1145-50; Kang, Cancer. Res. 2010, 70, 1173-83). Also, it reduces the risk of women cervical cancer development. Caffeine reduces a chance of prostate cancer formation in men by 60%. The same effect was observed in ability to prevent breast, colon and hepatic cancer (Hepatology, 2007, 46, 430-435). Caffeine enhances doxorubicin, cisplatin activity in metastatic carcinomas, lymphomas, bone and soft tissue sarcomas (Hayashi, Anticancer Res., 2005, 25, 2399-2406). Also, caffeine effectively inhibits breast cancer resistance protein (BCRP) multidrug resistance (MDR) on MCF-7 and MCF-7/MX100 (mitoxantrone-resistant) cell lines. One of the advantages of caffeine derivatives action is the ability to cross through the BBB. It opens the possibility to cure malignant diseases, such as neuroblastoma and glioblastoma multiforme, in the brain (Vartanyan, Psychopharm. Biol. Narc., 2005, 5, 1093-1095). Drugs used in neuro-oncology (temodar, carmustine (BCNU), lomusthine (CCNU), etc.) have a limited ability to cross through the BBB and are highly toxic. In a series of caffeine analogues, such as 8-(3-(dimethylamino)propoxy)caffeine (proxyfeine), antitumor agents were developed, however introduction in the clinic of the EU
and the US interferes, due to high levels of toxicity (LD50=355 mg/kg), as well as a large number of serious side effects. Proxyfeine (RU 2166948, 20.05.2001) is used in chemotherapy for cancer patients at high risk of brain metastases and the rehabilitation of the metastatic lesions to the brain, as well as the early stages of cancer metastasis prevention in Russia and other countries.
/ \
N
ONN
Date Recue/Date Received 2021-07-07
To minimize side effects currently being developed antitumor drugs based on caffeine core. Caffeine derivatives possess CNS expression as calcium agonist or antagonist effect. Recent studies show that caffeine-containing coffee daily use is able to lower mouth and brain cancer formation up to 39% (Michaud, Am. J. Clin. Nutr. 2010, 92, 1145-50; Kang, Cancer. Res. 2010, 70, 1173-83). Also, it reduces the risk of women cervical cancer development. Caffeine reduces a chance of prostate cancer formation in men by 60%. The same effect was observed in ability to prevent breast, colon and hepatic cancer (Hepatology, 2007, 46, 430-435). Caffeine enhances doxorubicin, cisplatin activity in metastatic carcinomas, lymphomas, bone and soft tissue sarcomas (Hayashi, Anticancer Res., 2005, 25, 2399-2406). Also, caffeine effectively inhibits breast cancer resistance protein (BCRP) multidrug resistance (MDR) on MCF-7 and MCF-7/MX100 (mitoxantrone-resistant) cell lines. One of the advantages of caffeine derivatives action is the ability to cross through the BBB. It opens the possibility to cure malignant diseases, such as neuroblastoma and glioblastoma multiforme, in the brain (Vartanyan, Psychopharm. Biol. Narc., 2005, 5, 1093-1095). Drugs used in neuro-oncology (temodar, carmustine (BCNU), lomusthine (CCNU), etc.) have a limited ability to cross through the BBB and are highly toxic. In a series of caffeine analogues, such as 8-(3-(dimethylamino)propoxy)caffeine (proxyfeine), antitumor agents were developed, however introduction in the clinic of the EU
and the US interferes, due to high levels of toxicity (LD50=355 mg/kg), as well as a large number of serious side effects. Proxyfeine (RU 2166948, 20.05.2001) is used in chemotherapy for cancer patients at high risk of brain metastases and the rehabilitation of the metastatic lesions to the brain, as well as the early stages of cancer metastasis prevention in Russia and other countries.
/ \
N
ONN
Date Recue/Date Received 2021-07-07
3 Proxyfeine PCT Patent application No. W02008077557 discloses preparation of 8-ethynyl xanthine derivatives as selective A2A receptor antagonists and their use as medicines, for example, in the treatment of dopamine-related movement disorders, _________________________________________________ R3 ON N
8-Ethynyl xanthines wherein RI and R2 represent, e.g., hydrogen, C1_6alkyl, cycloalkyl, heterocycloalkyl, aryl (wherein these groups may be further substituted), etc.; R3 represents e.g., aryl, hetaryl group.
PCT Patent application No. W02014/143799 A2, 2014 discloses preparation of N7-benzyl 8-ethynyl xanthine derivatives as agents for treatment of short transient receptor potential channel 5 (TrpC5) disorders A2A receptor antagonists and their use as medicines, for example, in the treatment of dopamine-related movement disorders.
m (Ra)r, R3, N
¨R2 ONN
N-Benzy1-8-ethynyl xanthines THE PRESENT INVENTION
We have discovered that certain ethynylxanthine derivatives exhibit high antiproliferative activity against various tumor cell lines. Therefore, these substances may be therapeutically beneficial in the treatment of tumors. These substances may be administered in the form of a pharmaceutical composition, wherein they are present together with one or more pharmaceutically acceptable diluents, carriers, or excipients.
OBJECTS OF THE INVENTION
It is an object of the present invention to provide novel antiproliferative compounds, methods for their synthesis and use for treatment and/or prevention cancer.
Date Recue/Date Received 2021-07-07
8-Ethynyl xanthines wherein RI and R2 represent, e.g., hydrogen, C1_6alkyl, cycloalkyl, heterocycloalkyl, aryl (wherein these groups may be further substituted), etc.; R3 represents e.g., aryl, hetaryl group.
PCT Patent application No. W02014/143799 A2, 2014 discloses preparation of N7-benzyl 8-ethynyl xanthine derivatives as agents for treatment of short transient receptor potential channel 5 (TrpC5) disorders A2A receptor antagonists and their use as medicines, for example, in the treatment of dopamine-related movement disorders.
m (Ra)r, R3, N
¨R2 ONN
N-Benzy1-8-ethynyl xanthines THE PRESENT INVENTION
We have discovered that certain ethynylxanthine derivatives exhibit high antiproliferative activity against various tumor cell lines. Therefore, these substances may be therapeutically beneficial in the treatment of tumors. These substances may be administered in the form of a pharmaceutical composition, wherein they are present together with one or more pharmaceutically acceptable diluents, carriers, or excipients.
OBJECTS OF THE INVENTION
It is an object of the present invention to provide novel antiproliferative compounds, methods for their synthesis and use for treatment and/or prevention cancer.
Date Recue/Date Received 2021-07-07
4 SUMMARY OF THE INVENTION
What we therefore believe to be comprised by our invention may be summarized inter alia in the following words:
A compound selected from those of Formula I
Nz = _____________________________________________ R4 1, IR' wherein RI represents hydrogen, C1_4alkyl, hydroxy-C2_4alkyl, C1_3alkoxy-C2_4a1kyl, CI-3alkylcarbonyl-C1_4alkyl or C1_3alkyl(C1_3alkyl)amino-C2_4alkyl;
R2 represents C1_4alkyl, hydroxy-C2_4alkyl, C1_4alkylcarbonyl-C1_4alkyl, C1_3alkoxy-C2-4a1ky1, C1_3alkyl(C1_3alkyl)amino-C2_4alkyl or halo-C2_4a1ky1;
R3 represents CI4alkyl, allyl or C1_3a1k0xy-C2_4a1ky1;
R4 represents C1_4alkyl, hydroxy-C1_4alkyl, Ci_3a1koxy-C1_4alkyl, amino-C1_4alkyl, 1-hydroxy-di-(C1-3alkyl)methyl, 1-amino-di-(C13alkyl)methyl, 1-hydroxy-cyclo-C3-6a1ky1, 1-amino-cyclo-C3_6a1ky1, 1 -(hy droxy-C1_3alkyl)-cy cloC3_6a1ky1, Ci-3a1ky1amin0-C1-3alkyl, C1_3alkyl(C1_3alkyl)amino-C1_3alkyl, di-(Ci_3alkoxy-C2_4alkyl)-amino-C1_3alkyl, heterocyclyl-C13alkyl, aryl or heteroaryl;
with the proviso that if substituent R3 is at purine N(7) atom the dotted line between N(7) and C(8) represents no bond, and the dotted line between C(8) and N(9) represents chemical bond;
and with the proviso that if substituent R3 is at purine N(9) atom the dotted line between N(7) and C(8) represents chemical bond, and the dotted line between C(8) and N(9) represents no bond;
Date Recue/Date Received 2021-07-07
What we therefore believe to be comprised by our invention may be summarized inter alia in the following words:
A compound selected from those of Formula I
Nz = _____________________________________________ R4 1, IR' wherein RI represents hydrogen, C1_4alkyl, hydroxy-C2_4alkyl, C1_3alkoxy-C2_4a1kyl, CI-3alkylcarbonyl-C1_4alkyl or C1_3alkyl(C1_3alkyl)amino-C2_4alkyl;
R2 represents C1_4alkyl, hydroxy-C2_4alkyl, C1_4alkylcarbonyl-C1_4alkyl, C1_3alkoxy-C2-4a1ky1, C1_3alkyl(C1_3alkyl)amino-C2_4alkyl or halo-C2_4a1ky1;
R3 represents CI4alkyl, allyl or C1_3a1k0xy-C2_4a1ky1;
R4 represents C1_4alkyl, hydroxy-C1_4alkyl, Ci_3a1koxy-C1_4alkyl, amino-C1_4alkyl, 1-hydroxy-di-(C1-3alkyl)methyl, 1-amino-di-(C13alkyl)methyl, 1-hydroxy-cyclo-C3-6a1ky1, 1-amino-cyclo-C3_6a1ky1, 1 -(hy droxy-C1_3alkyl)-cy cloC3_6a1ky1, Ci-3a1ky1amin0-C1-3alkyl, C1_3alkyl(C1_3alkyl)amino-C1_3alkyl, di-(Ci_3alkoxy-C2_4alkyl)-amino-C1_3alkyl, heterocyclyl-C13alkyl, aryl or heteroaryl;
with the proviso that if substituent R3 is at purine N(7) atom the dotted line between N(7) and C(8) represents no bond, and the dotted line between C(8) and N(9) represents chemical bond;
and with the proviso that if substituent R3 is at purine N(9) atom the dotted line between N(7) and C(8) represents chemical bond, and the dotted line between C(8) and N(9) represents no bond;
Date Recue/Date Received 2021-07-07
5 wherein the term "heterocycly1" represents saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heterocyclyl may be azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl;
the term "aryl" represents phenyl or phenyl substituted by one or more substituents selected independently from halogen, cyano, C1_4alkoxycarbonyl; N-C1_ 4alkylaminocarbonyl, N,N-di-(C1-3alkyl)aminocarbonyl, CH2OH, trifluoromethyl, CI-4alkyl, allyl, C2_4alkynyl, C1_4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alkoxy, hydroxy-Ci_4alkyl, Ci_3alkoxy-Ci_4alkyl, Ci_3alkoxy-C2_4alkoxy, di-(C1-3alkyl)amino, di-(C1_3alkyl)amino-C1_3alkyl, di-(C1_3a1kyl)amino-C2_4alkoxy, C1_4alkylsulfonylamino and Ci_4alkyl-aminosulfonyl;
the term "heteroaryl" represents an aromatic 5 or 6 membered ring comprising one to three heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl is unsubstituted or is substituted by one or more substituents selected independently from halogen, cyano, trifluoromethyl, C1_4alkyl, C1-4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6a1k0xy, C1_3a1k0xy-C1_4a1ky1, cyclo-C3_6a1ky1amin0 and di -(C i_3alkyl)amino;
its optical isomers, and pharmaceutically acceptable acid addition salts and hydrates and solvates thereof In some embodiments, R4 represents hydroxy-C1_4alkyl, amino-C1_4alkyl, 1-hydroxy-di-(C1_3alkyl)methyl, 1-amino-di-(C1-3alkyl)methyl, 1-hydroxy-cyclo-C3-6a1ky1, amino-cyclo-C3_6alkyl, 1 -(hydroxy-C1_3alkyl)-cycloC3_6alkyl, C1_3alkyl(C1_ 3alkyl)amino-C1_3alkyl, di-(C1-3alkoxy-C2_4alkyl)-amino-C1_3alkyl, heterocyclyl-Ci-3a1ky1 or aryl.
In some embodiments, R2 and R3 each independently represent C1_4alkyl or CI_ 3alkoxy-C2_4alkyl with the proviso that if R2 is ethyl, R3 is methyl and R4 is hydroxy-ethyl, then RI is not a hydrogen.
Date Recue/Date Received 2021-07-07
the term "aryl" represents phenyl or phenyl substituted by one or more substituents selected independently from halogen, cyano, C1_4alkoxycarbonyl; N-C1_ 4alkylaminocarbonyl, N,N-di-(C1-3alkyl)aminocarbonyl, CH2OH, trifluoromethyl, CI-4alkyl, allyl, C2_4alkynyl, C1_4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alkoxy, hydroxy-Ci_4alkyl, Ci_3alkoxy-Ci_4alkyl, Ci_3alkoxy-C2_4alkoxy, di-(C1-3alkyl)amino, di-(C1_3alkyl)amino-C1_3alkyl, di-(C1_3a1kyl)amino-C2_4alkoxy, C1_4alkylsulfonylamino and Ci_4alkyl-aminosulfonyl;
the term "heteroaryl" represents an aromatic 5 or 6 membered ring comprising one to three heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl is unsubstituted or is substituted by one or more substituents selected independently from halogen, cyano, trifluoromethyl, C1_4alkyl, C1-4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6a1k0xy, C1_3a1k0xy-C1_4a1ky1, cyclo-C3_6a1ky1amin0 and di -(C i_3alkyl)amino;
its optical isomers, and pharmaceutically acceptable acid addition salts and hydrates and solvates thereof In some embodiments, R4 represents hydroxy-C1_4alkyl, amino-C1_4alkyl, 1-hydroxy-di-(C1_3alkyl)methyl, 1-amino-di-(C1-3alkyl)methyl, 1-hydroxy-cyclo-C3-6a1ky1, amino-cyclo-C3_6alkyl, 1 -(hydroxy-C1_3alkyl)-cycloC3_6alkyl, C1_3alkyl(C1_ 3alkyl)amino-C1_3alkyl, di-(C1-3alkoxy-C2_4alkyl)-amino-C1_3alkyl, heterocyclyl-Ci-3a1ky1 or aryl.
In some embodiments, R2 and R3 each independently represent C1_4alkyl or CI_ 3alkoxy-C2_4alkyl with the proviso that if R2 is ethyl, R3 is methyl and R4 is hydroxy-ethyl, then RI is not a hydrogen.
Date Recue/Date Received 2021-07-07
6 In some embodiments, R2 and R3 each represent methyl.
In some embodiments, R1 represents methyl or 5-oxohexyl.
Specific compounds of Formula I within the present invention include but are not limited to:
8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexypethyny1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione, 8-(3-(Dimethylamino)prop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione, 8-(3-(bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-(pyrrolidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 1,3 ,7-Trimethy1-8-(3-(pip eridin-1 -y 1)prop-1-yn-1 -y1)-1H-purine-2,6(3H,7H)-di one, 8-(3-(Azepan-1-yl)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-morpholinoprop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 8-(3-Hy droxy -3 -methylbut-l-yn-1 -y1)-3,7-dimethy1-1 -(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexypethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-(3-(Bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(piperidin-1-y1)prop-1-yn-1 -y1)-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,7H)-dione, 1,3,9-Trimethy1-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,9H)-dione, 1,3,9-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,9H)-dione Date Recue/Date Received 2021-07-07
In some embodiments, R1 represents methyl or 5-oxohexyl.
Specific compounds of Formula I within the present invention include but are not limited to:
8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexypethyny1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione, 8-(3-(Dimethylamino)prop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione, 8-(3-(bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-(pyrrolidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 1,3 ,7-Trimethy1-8-(3-(pip eridin-1 -y 1)prop-1-yn-1 -y1)-1H-purine-2,6(3H,7H)-di one, 8-(3-(Azepan-1-yl)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-morpholinoprop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 8-(3-Hy droxy -3 -methylbut-l-yn-1 -y1)-3,7-dimethy1-1 -(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexypethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-(3-(Bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(piperidin-1-y1)prop-1-yn-1 -y1)-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,7H)-dione, 1,3,9-Trimethy1-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,9H)-dione, 1,3,9-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,9H)-dione Date Recue/Date Received 2021-07-07
7 and optical isomers, polymorphs, and pharmaceutically-acceptable acid addition salts, hydrates, and solvates thereof The invention also relates to a manufacturing process of a compound selected from those of Formula! as defined above, comprising reaction of a compound of Formula ' ONN
II
wherein RI, R2 and R3 are as defined for Formula I above, with a compound of Formula!!!:
¨ ____________________________________ R4 III
wherein R4 is as defined for Formula! above, optionally in the presence of base in an appropriate solvent (e.g., DIEA in DMF, NMP, DMAC or Et0Ac), in the presence of CuI and palladium catalyst generated in situ (e.g., from PdC12 or Pd(OAc)2 and PPh3) or commercially available (Ph3P)4Pd to yield a compound of Formula!, which may be converted, if desired, into an optical isomer, polymorph, pharmaceutically-acceptable salt, hydrate or solvate.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "C1_4alkyl" represents straight or branched chain alkyl groups having 1, 2, 3 or 4 carbon atoms, examples of such alkyl groups include methyl, ethyl, n-propyl, 2-propyl, n-butyl, 2-butyl, iso-butyl and tert-butyl.
The term "cyclo-C3_6alkyl" represents monocyclic alkyl groups having 3, 4, 5 or 6 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
Date Recue/Date Received 2021-07-07
II
wherein RI, R2 and R3 are as defined for Formula I above, with a compound of Formula!!!:
¨ ____________________________________ R4 III
wherein R4 is as defined for Formula! above, optionally in the presence of base in an appropriate solvent (e.g., DIEA in DMF, NMP, DMAC or Et0Ac), in the presence of CuI and palladium catalyst generated in situ (e.g., from PdC12 or Pd(OAc)2 and PPh3) or commercially available (Ph3P)4Pd to yield a compound of Formula!, which may be converted, if desired, into an optical isomer, polymorph, pharmaceutically-acceptable salt, hydrate or solvate.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "C1_4alkyl" represents straight or branched chain alkyl groups having 1, 2, 3 or 4 carbon atoms, examples of such alkyl groups include methyl, ethyl, n-propyl, 2-propyl, n-butyl, 2-butyl, iso-butyl and tert-butyl.
The term "cyclo-C3_6alkyl" represents monocyclic alkyl groups having 3, 4, 5 or 6 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
Date Recue/Date Received 2021-07-07
8 The term "heterocycly1" represents a saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, examples of such heterocyclyl groups include azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl.
The term "halo" or "halogen" represents fluorine, chlorine, bromine and iodine.
In addition, using methods known to those skilled in the art, analogs and derivatives of the compounds of the invention can be created which have improved therapeutic efficacy, i.e., higher potency and/or selectivity at a specific targeted receptor type, greater ability to penetrate mammalian blood-brain barriers, fewer side effects, etc.
It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. It is to be understood that the present invention encompasses any racemic, optically-active, tautomeric, or stereoisomeric form of a compound of the invention, which possesses the useful properties described herein.
For therapeutic use, the compounds of Formula I can be in the form of a pharmaceutically acceptable salt or a solvate. The term "pharmaceutically acceptable"
refers here to the therapeutically active non-toxic salt forms, which the compounds of Formula I are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids such as hydrochloric acid, hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids such as acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, methanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, 2-hydroxybenzoic, and like acids.
Conversely, the salt may be converted to the free base by treatment with alkali.
Scheme 1 describes the preparation of compounds of Formula I of the present invention. All of the starting materials II are prepared by representative procedures described in Schemes 2 and 3, by procedures well known to one of ordinary skill in organic chemistry or can be obtained commercially. All of the final compounds of the present invention are prepared by procedures described in these charts or by Date Recue/Date Received 2021-07-07
The term "halo" or "halogen" represents fluorine, chlorine, bromine and iodine.
In addition, using methods known to those skilled in the art, analogs and derivatives of the compounds of the invention can be created which have improved therapeutic efficacy, i.e., higher potency and/or selectivity at a specific targeted receptor type, greater ability to penetrate mammalian blood-brain barriers, fewer side effects, etc.
It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. It is to be understood that the present invention encompasses any racemic, optically-active, tautomeric, or stereoisomeric form of a compound of the invention, which possesses the useful properties described herein.
For therapeutic use, the compounds of Formula I can be in the form of a pharmaceutically acceptable salt or a solvate. The term "pharmaceutically acceptable"
refers here to the therapeutically active non-toxic salt forms, which the compounds of Formula I are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids such as hydrochloric acid, hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids such as acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, methanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, 2-hydroxybenzoic, and like acids.
Conversely, the salt may be converted to the free base by treatment with alkali.
Scheme 1 describes the preparation of compounds of Formula I of the present invention. All of the starting materials II are prepared by representative procedures described in Schemes 2 and 3, by procedures well known to one of ordinary skill in organic chemistry or can be obtained commercially. All of the final compounds of the present invention are prepared by procedures described in these charts or by Date Recue/Date Received 2021-07-07
9 procedures analogous thereto, which procedures would be well known to one of ordinary skill in organic chemistry. All of the variables used in the schemes are as defined below or as in the claims.
We have found that product yields in palladium catalyzed cross-coupling of terminal acetylenes and 8-bromoxanthines strongly depends on the nature of catalyst and solvent. In accordance with experimental data, reaction of terminal acetylenes III with 8-bromoxanthines under routine experimental conditions (Methods A and B) in general led to the formation of the corresponding 8-ethynylxanthines I in very low yields. Suprisingly, we have found that use of the mixture of N-methylpyrrolidine and toluene (1:1) (Method C) gave the desired products in high yields. Alternative method was elaborated (Method D). Performing the reaction in ethyl acetate and using 2 mol-% of Pd(PPh3)4 and 2 mol-% of PdC12 decreases the cost of reaction. It should be noted that in the representative example the treatment of 8-bromocaffeine with two equivalents of 2-methylbut-3-yn-2-ol under conditions of Method D led to the formation of desired 8-(3-hy droxy-3-methy lbut-1 -yn-1 -y1)-1,3 ,7-trimethy1-1H-purine-2,6(3H,7H)-dione (I-1) in 55% yield and by-product 8-RE)-5-hydroxy-2-(1-hydroxy-1 -methylethyl)-5 -methylhex-1 -en-3-ynyl] -1,3 ,7-trimethy1-1H-purine-2,6(3H,7H)-dione in 26% yield similar to the method elaborated previously (Arsenyan, Tetrahedron Left., 2013, 54, 6524-6528).
Scheme 1. General procedure toward compounds of Formula I.
R1'N R1 R3 Br + I R4 'N V __ R4 ONN ONN
F'R2 II III I
Reaction conditions:
Method A. (Ph3P)2PdC12, CuI, N-methylpyrrolidine or DMF, DIEA, 50 C;
Method B. Pd(OAc)2, Ph3P, CuI, N-methylpyrrolidine or DMAC, DIEA, 55 C;
Method C. Pd(OAc)2, Ph3P, CuI, N-methylpyrrolidine/toluene (1:1), DIEA, 50 C;
Method D. Pd(PPh3)4, PdC12, Ph3P, Cul, ethyl acetate, DIEA, 40 C.
Date Recue/Date Received 2021-07-07
We have found that product yields in palladium catalyzed cross-coupling of terminal acetylenes and 8-bromoxanthines strongly depends on the nature of catalyst and solvent. In accordance with experimental data, reaction of terminal acetylenes III with 8-bromoxanthines under routine experimental conditions (Methods A and B) in general led to the formation of the corresponding 8-ethynylxanthines I in very low yields. Suprisingly, we have found that use of the mixture of N-methylpyrrolidine and toluene (1:1) (Method C) gave the desired products in high yields. Alternative method was elaborated (Method D). Performing the reaction in ethyl acetate and using 2 mol-% of Pd(PPh3)4 and 2 mol-% of PdC12 decreases the cost of reaction. It should be noted that in the representative example the treatment of 8-bromocaffeine with two equivalents of 2-methylbut-3-yn-2-ol under conditions of Method D led to the formation of desired 8-(3-hy droxy-3-methy lbut-1 -yn-1 -y1)-1,3 ,7-trimethy1-1H-purine-2,6(3H,7H)-dione (I-1) in 55% yield and by-product 8-RE)-5-hydroxy-2-(1-hydroxy-1 -methylethyl)-5 -methylhex-1 -en-3-ynyl] -1,3 ,7-trimethy1-1H-purine-2,6(3H,7H)-dione in 26% yield similar to the method elaborated previously (Arsenyan, Tetrahedron Left., 2013, 54, 6524-6528).
Scheme 1. General procedure toward compounds of Formula I.
R1'N R1 R3 Br + I R4 'N V __ R4 ONN ONN
F'R2 II III I
Reaction conditions:
Method A. (Ph3P)2PdC12, CuI, N-methylpyrrolidine or DMF, DIEA, 50 C;
Method B. Pd(OAc)2, Ph3P, CuI, N-methylpyrrolidine or DMAC, DIEA, 55 C;
Method C. Pd(OAc)2, Ph3P, CuI, N-methylpyrrolidine/toluene (1:1), DIEA, 50 C;
Method D. Pd(PPh3)4, PdC12, Ph3P, Cul, ethyl acetate, DIEA, 40 C.
Date Recue/Date Received 2021-07-07
10 Compounds II, wherein R3 is at purine N(7), can be prepared by bromination of position 8 of corresponding 8-unsubstituted 1,3,7-substituted 1H-purine-2,6(3H,7H)-diones. Representative method for the synthesis of compound II wherein R1 and are methyl groups shown in Scheme 2. Commercially available caffeine (1) and pentoxifylline (2) are brominated in position 8 by N-bromosuccinimide (NBS) in dichloromethane in analogy to published procedure [Synlett, 2012, 23, 1191-1198].
Both products 3 and 4 were isolated in almost quantitative yields.
Scheme 2. General procedure for the preparation of 8-bromo 1H-purine-2,6(3H,7H)-diones II, wherein R3 is at purine N(7) (3, 4).
N NBSN N
I I
C) N N ONN
I (RI = Me) 3 (RI = Me) 2 (RI = MeC(0)(CH2)4) 4 (RI = MeC(0)(CH2)4) Compounds II, wherein R3 is at purine N(9), can be prepared by bromination of position 8 of respective 8-unsubstituted 1,3,9-substituted 1H-purine-2,6(3H,9H)-diones. Representative method for the synthesis of compound II wherein RI, R2 and R3 are methyl groups (compound 11) is shown in Scheme 3. Thus, 1,3-dimethy1-6-chlorouracil (6) was prepared by the treatment of 1,3-dimethylbarbituric acid (5) in phosphorous oxychloride (P0C13) with water followed by heating under reflux.
Then treatment of compound 6 with a mixture of fuming nitric acid and sulfuric acid resulted in formation of 6-chloro-1,3-dimethy1-5-nitropyrimidine-2,4(1H,3H)-dione (7). Next, choro substituent was substituted by methylamino moiety to give intermediate 8 and nitro group was reducted by hydrogen using palladium on charcoal as a catalyst. Finally, condensation of 5-amino-1,3-dimethy1-6-methylamino-pyrimidine-2,4(1H,3H)-dione (9) with formic acid gave 1,3,9-trimethy1-3,9-dihydro-purin-2,6 (3H,9H)-di one (10). Necessary 8-bromo-1,3,9-trimethy1-3,9-dihy dropurin-2,6(3H,9H)-dione (11) was obtained in the reaction of compound 10 with N-bromosuccinimide (NBS) in acetonitrile. The procedures shown in the Scheme 3 are general and can be used to prepare analogous 8-bromo 1,3,9-substituted 1H-purine-2,6(3H,9H)-diones.
Date Recue/Date Received 2021-07-07
Both products 3 and 4 were isolated in almost quantitative yields.
Scheme 2. General procedure for the preparation of 8-bromo 1H-purine-2,6(3H,7H)-diones II, wherein R3 is at purine N(7) (3, 4).
N NBSN N
I I
C) N N ONN
I (RI = Me) 3 (RI = Me) 2 (RI = MeC(0)(CH2)4) 4 (RI = MeC(0)(CH2)4) Compounds II, wherein R3 is at purine N(9), can be prepared by bromination of position 8 of respective 8-unsubstituted 1,3,9-substituted 1H-purine-2,6(3H,9H)-diones. Representative method for the synthesis of compound II wherein RI, R2 and R3 are methyl groups (compound 11) is shown in Scheme 3. Thus, 1,3-dimethy1-6-chlorouracil (6) was prepared by the treatment of 1,3-dimethylbarbituric acid (5) in phosphorous oxychloride (P0C13) with water followed by heating under reflux.
Then treatment of compound 6 with a mixture of fuming nitric acid and sulfuric acid resulted in formation of 6-chloro-1,3-dimethy1-5-nitropyrimidine-2,4(1H,3H)-dione (7). Next, choro substituent was substituted by methylamino moiety to give intermediate 8 and nitro group was reducted by hydrogen using palladium on charcoal as a catalyst. Finally, condensation of 5-amino-1,3-dimethy1-6-methylamino-pyrimidine-2,4(1H,3H)-dione (9) with formic acid gave 1,3,9-trimethy1-3,9-dihydro-purin-2,6 (3H,9H)-di one (10). Necessary 8-bromo-1,3,9-trimethy1-3,9-dihy dropurin-2,6(3H,9H)-dione (11) was obtained in the reaction of compound 10 with N-bromosuccinimide (NBS) in acetonitrile. The procedures shown in the Scheme 3 are general and can be used to prepare analogous 8-bromo 1,3,9-substituted 1H-purine-2,6(3H,9H)-diones.
Date Recue/Date Received 2021-07-07
11 Scheme 3. Preparation of 8-bromo 1H-purine-2,6(3H,9H)-dione 11 (II, wherein R3 is at purine N(9)).
N 2 MeNH2 NO2 I I
0 N 0 ONCI H2SO4 ONCI H20 (:)N NH
I \
H2 N)./NH2 HCO2H
NBS
I I I
Pd/C ONNH
It will be appreciated that in the above transformations it may be necessary or desirable to protect any sensitive groups in the molecule of the compound in question in order to avoid undesirable side reactions.
EXPERIMENTAL PART
The compounds and their preparation of the present invention will be better understood in connection with the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention.
Hereinafter, "DMF" is defined as N,N-dimethylformamide, "DMAC" is defined as N,N-dimethylacetamide, "NMP" is defined as N-methylpyrrolidone, "DMSO" as dimethyl sulfoxide, "HCl" as hydrochloric acid, õaq. N143" as aqueous ammonia solution, õ"MeCN" as acetonitrile, "DIEA" as diisopropylethylamine, "Et0Ac" as ethyl acetate, "rt" as room temperature.
Intermediate 3.
8-Bromo-1,3,7-trimethy1-1H-purine-2,6(3H,71/)-d lone (3) N IBr To a round-botton flask containing freshly distilled CH2C12 (150 mL) was added caffeine (10.0 g, 0.05 mol) and NBS (17.6 g, 0.10 mol). When the solids had Date Recue/Date Received 2021-07-07
N 2 MeNH2 NO2 I I
0 N 0 ONCI H2SO4 ONCI H20 (:)N NH
I \
H2 N)./NH2 HCO2H
NBS
I I I
Pd/C ONNH
It will be appreciated that in the above transformations it may be necessary or desirable to protect any sensitive groups in the molecule of the compound in question in order to avoid undesirable side reactions.
EXPERIMENTAL PART
The compounds and their preparation of the present invention will be better understood in connection with the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention.
Hereinafter, "DMF" is defined as N,N-dimethylformamide, "DMAC" is defined as N,N-dimethylacetamide, "NMP" is defined as N-methylpyrrolidone, "DMSO" as dimethyl sulfoxide, "HCl" as hydrochloric acid, õaq. N143" as aqueous ammonia solution, õ"MeCN" as acetonitrile, "DIEA" as diisopropylethylamine, "Et0Ac" as ethyl acetate, "rt" as room temperature.
Intermediate 3.
8-Bromo-1,3,7-trimethy1-1H-purine-2,6(3H,71/)-d lone (3) N IBr To a round-botton flask containing freshly distilled CH2C12 (150 mL) was added caffeine (10.0 g, 0.05 mol) and NBS (17.6 g, 0.10 mol). When the solids had Date Recue/Date Received 2021-07-07
12 dissolved in solvent, water (50 mL) was added and the reaction mixture was stirred for 5 days. Then cold 2 M aq.NaOH (30 mL) was added and the mixture was shaken till decolorization. The organic layer was separated, washed with water (2x200 mL), dried over sodium sulfate, filtered and evaporated to give the title compound (13.5 g, 99%). Ili NMR (CDC13/TMS, 400 MHz) 8 (ppm): 3.41 (s, 3H, CH3), 3.57 (s, 3H, CH3), 3.97 (s, 3H, CH3).
Intermediate 4 8-Bromo-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,71/)-dione (4) I
ONN
To a round-botton flask containing freshly distilled CH2C12 (150 mL) was added pentoxifylline (13.4 g, 0.05 mol) and NBS (17.6 g, 0.10 mol). When the solids had dissolved, water (50 mL) was added and the reaction mixture stirred for 5 days. Then cold 2 M aq. NaOH (30 mL) was added and the mixture was shaken till decolorization.
The organic layer was separated, washed with water (2x200 mL), dried over sodium sulfate, filtered and evaporated to give the title compound (16.95 g, 95%). 11-(CDC13/TMS, 400 MHz) (ppm): 1.61-1.67 (m, 4H), 2.14 (s, 3H), 2.49 (t, 2H), 3.54 (s, 3H), 3.95 (s, 3H), 3.99 (t, 2H).
Intermediate 11.
8-Bromo-1,3,9-trimethy1-1H-purine-2,6(3H,91/)-dione (11).
I
ONN
\
a) 6-Chloro-1,3-dimethylpyrimidine-2,4(1H,31/)-dione (6).
To a suspension of 1,3-dimethylbarbituric acid (7.8 g, 50 mmol) in POC13 (60 mL) was slowly added water (2.5 mL, 0.14 mol) and the reaction mixture was refltixed for 1 h under nitrogen atmosphere. An excess of POC13 was distilled off under reduced presssure and the residue was quenched with 40 mL of ice water. The mixture was Date Recue/Date Received 2021-07-07
Intermediate 4 8-Bromo-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,71/)-dione (4) I
ONN
To a round-botton flask containing freshly distilled CH2C12 (150 mL) was added pentoxifylline (13.4 g, 0.05 mol) and NBS (17.6 g, 0.10 mol). When the solids had dissolved, water (50 mL) was added and the reaction mixture stirred for 5 days. Then cold 2 M aq. NaOH (30 mL) was added and the mixture was shaken till decolorization.
The organic layer was separated, washed with water (2x200 mL), dried over sodium sulfate, filtered and evaporated to give the title compound (16.95 g, 95%). 11-(CDC13/TMS, 400 MHz) (ppm): 1.61-1.67 (m, 4H), 2.14 (s, 3H), 2.49 (t, 2H), 3.54 (s, 3H), 3.95 (s, 3H), 3.99 (t, 2H).
Intermediate 11.
8-Bromo-1,3,9-trimethy1-1H-purine-2,6(3H,91/)-dione (11).
I
ONN
\
a) 6-Chloro-1,3-dimethylpyrimidine-2,4(1H,31/)-dione (6).
To a suspension of 1,3-dimethylbarbituric acid (7.8 g, 50 mmol) in POC13 (60 mL) was slowly added water (2.5 mL, 0.14 mol) and the reaction mixture was refltixed for 1 h under nitrogen atmosphere. An excess of POC13 was distilled off under reduced presssure and the residue was quenched with 40 mL of ice water. The mixture was Date Recue/Date Received 2021-07-07
13 extracted with chloroform (2x100 mL). The organic phase was dried over anhydrous Na2SO4, evaporated to dryness, and the residue crystallized with ether to give the title compound (8.0 g) as a yellow crystals. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 3.10 and 3.15 (both s, both 3H), 6.07 (s, 1H).
b) 6-Chloro-1,3-dimethy1-5-nitropyrimidine-2,4(1H,3H)-dione (7).
Compound 6 (15 g, 74.5 mmol) was added portionwise to a cooled solution of conc.
H2SO4 (40 mL) . The reaction temperature was maintained below 10 C. Fuming nitric acid (15 mL) was added dropwise to the above reaction mixture and it was stirred for 2 h at the same temperature. The reaction nixture was poured onto the ice cold water (500 mL) and extracted with chloroform (2x260 mL). The combined organic extracts were washed with water (260 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give the title compound (12.0 g) as a yellow solid.
(400 MHz, DMSO-d6) 8 (ppm): 3.07 and 3.26 (both s, both 3H).
c) 1,3-Dimethy1-6-methylamino-5-nitropyrimidine-2,4(1H,3H)-dione (8).
To a stirred solution of 6-chloro-1,3-dimethy1-5-nitropyrimidine-2,4(1H,3H)-dione (7) (11.0 g, 50.1 mmol) in chloroform (90 mL) was added dropwise a solution of 40%
aq.
methylamine (7.76 mL, 100.2 mmol) in dichloromethane (20 mL) under nitrogen atmosphere. After stirring at room temperature for 1 h the reaction mixture was concentrated under reduced pressure. The residue was crystallized from ether to give the title compound (12.5 g) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 2.49, 2.75 and 3.35 (all s, all 3H), 7.74 (br s, 1H).
d) 5-Amino-1,3-dimethy1-6-methylamino-pyrimidine-2,4(1H,3H)-dione (9).
To a stirred solution of 1,3-dimethy1-6-methylamino-5-nitropyrimidine-2,4(1H,3H)-dione (8) (2 g, 10 mmol) in wet methanol (140 mL) was added 10% Pd-C (1 g) under hydrogen balloon atmosphere at room temperature. After overnight stirring, the reaction mixture was filtered and the filtrate was concentrated to give the title compound (1.5 g). 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 2.89 (d, 3H), 3.31 (s, 3H), 3.40 (s, 3H), 4.75 (br s, 1H). MS (El) m/z: 185 [Mr.
e) 1,3,9-Trimethy1-1H-purine-2,6(3H,91/)-dione (10).
A mixture of 5-amino-1,3-dimethy1-6-methylamino-pyrimidine-2,4(1H,311)-dione (9) (1.5 g) and formic acid (10 mL) was refh.med for 3 h under nitrogen atmosphere. An excess of formic acid was evaporated under reduce pressure. The residue was extracted with CH2C12, washed with aq. Na2CO3, dried over Na2SO4 and evaporated Date Recue/Date Received 2021-07-07
b) 6-Chloro-1,3-dimethy1-5-nitropyrimidine-2,4(1H,3H)-dione (7).
Compound 6 (15 g, 74.5 mmol) was added portionwise to a cooled solution of conc.
H2SO4 (40 mL) . The reaction temperature was maintained below 10 C. Fuming nitric acid (15 mL) was added dropwise to the above reaction mixture and it was stirred for 2 h at the same temperature. The reaction nixture was poured onto the ice cold water (500 mL) and extracted with chloroform (2x260 mL). The combined organic extracts were washed with water (260 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give the title compound (12.0 g) as a yellow solid.
(400 MHz, DMSO-d6) 8 (ppm): 3.07 and 3.26 (both s, both 3H).
c) 1,3-Dimethy1-6-methylamino-5-nitropyrimidine-2,4(1H,3H)-dione (8).
To a stirred solution of 6-chloro-1,3-dimethy1-5-nitropyrimidine-2,4(1H,3H)-dione (7) (11.0 g, 50.1 mmol) in chloroform (90 mL) was added dropwise a solution of 40%
aq.
methylamine (7.76 mL, 100.2 mmol) in dichloromethane (20 mL) under nitrogen atmosphere. After stirring at room temperature for 1 h the reaction mixture was concentrated under reduced pressure. The residue was crystallized from ether to give the title compound (12.5 g) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 2.49, 2.75 and 3.35 (all s, all 3H), 7.74 (br s, 1H).
d) 5-Amino-1,3-dimethy1-6-methylamino-pyrimidine-2,4(1H,3H)-dione (9).
To a stirred solution of 1,3-dimethy1-6-methylamino-5-nitropyrimidine-2,4(1H,3H)-dione (8) (2 g, 10 mmol) in wet methanol (140 mL) was added 10% Pd-C (1 g) under hydrogen balloon atmosphere at room temperature. After overnight stirring, the reaction mixture was filtered and the filtrate was concentrated to give the title compound (1.5 g). 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 2.89 (d, 3H), 3.31 (s, 3H), 3.40 (s, 3H), 4.75 (br s, 1H). MS (El) m/z: 185 [Mr.
e) 1,3,9-Trimethy1-1H-purine-2,6(3H,91/)-dione (10).
A mixture of 5-amino-1,3-dimethy1-6-methylamino-pyrimidine-2,4(1H,311)-dione (9) (1.5 g) and formic acid (10 mL) was refh.med for 3 h under nitrogen atmosphere. An excess of formic acid was evaporated under reduce pressure. The residue was extracted with CH2C12, washed with aq. Na2CO3, dried over Na2SO4 and evaporated Date Recue/Date Received 2021-07-07
14 to dryness. The residue was purified by column chromatography (eluent CH2C12 :
Me0H, 10:1) to give the title compound (0.5 g) as a white solid. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 3.22, 3.68 and 3.93 (all s, all 3H), 7.66 (s, 1H). MS (El) m/z: 195 [M+2]+.
f) 8-Bromo-1,3,9-trimethy1-1H-purine-2,6(3H,9H)-dione (11).
A mixture of 1,3,9-trimethy1-1H-purine-2,6(3H,9H)-dione (10) (1.0 g, 5.15 mmol) and NBS (1.2 g, 6.7 mmol) in dry MeCN (40 mL) was stirred for 3 h at room temperature. Water (30 mL) and CH2C12 (150 mL) was added, the organic phase was separated, dried over Na2SO4 and evaporated to dryness. The residue was purified by column chromatography (CH2C12 : Me0H, 9:1) to give the title compound (0.57 g) as a white solid with m.p. >200 C. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 3.22, 3.69 and 3.88 (all s, all 3H). MS (El) m/z: 375 [M+21 .
Example 1 8-(3-Hydroxy-3-methylbut-1-yn-l-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione (1-1) OH
I
Method A. To a mixture of PdC12 (113 mg, 0.637 mmol), CuI (242 mg, 1.27 mmol), and triphenylphosphine (333 mg, 1.27 mmol) was added dry NMP or DMF (40 mL).
The reaction mixture was allowed to stir at 40 C for 15 min with simultaneous barbotation with argon. Then a solution of 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione (1.73 g, 6.37 mmol) and 2-methylbut-3-yn-2-ol (0.93 mL, 9.56 mmol) and dry DIEA (3.6 mL) was added and stirring was continued at 50 C
for 24 h. After cooling to rt, the reaction mixture was poured to Et0Ac (300 mL), washed with brine (80 mL) containing aq. NH3 (0.5 mL) and stirred at rt for the additional min. The aqueous phase was separated and the organic phase was washed with brine (3 x 80 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel using a mixture of water (containing 0.1% HC1) - MeCN (5% - 70%) as eluent to 30 give the title compound in 42% yield. mp = 180-182 C. 1H NMR
(CDC13/TMS, 400 MHz) (ppm): 1.63 (s, 6H), 3.36 (s, 3H), 3.51 (s, 3H), 3.52 (br s, 1H), 3.90 (s, 3H).
Date Recue/Date Received 2021-07-07
Me0H, 10:1) to give the title compound (0.5 g) as a white solid. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 3.22, 3.68 and 3.93 (all s, all 3H), 7.66 (s, 1H). MS (El) m/z: 195 [M+2]+.
f) 8-Bromo-1,3,9-trimethy1-1H-purine-2,6(3H,9H)-dione (11).
A mixture of 1,3,9-trimethy1-1H-purine-2,6(3H,9H)-dione (10) (1.0 g, 5.15 mmol) and NBS (1.2 g, 6.7 mmol) in dry MeCN (40 mL) was stirred for 3 h at room temperature. Water (30 mL) and CH2C12 (150 mL) was added, the organic phase was separated, dried over Na2SO4 and evaporated to dryness. The residue was purified by column chromatography (CH2C12 : Me0H, 9:1) to give the title compound (0.57 g) as a white solid with m.p. >200 C. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 3.22, 3.69 and 3.88 (all s, all 3H). MS (El) m/z: 375 [M+21 .
Example 1 8-(3-Hydroxy-3-methylbut-1-yn-l-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione (1-1) OH
I
Method A. To a mixture of PdC12 (113 mg, 0.637 mmol), CuI (242 mg, 1.27 mmol), and triphenylphosphine (333 mg, 1.27 mmol) was added dry NMP or DMF (40 mL).
The reaction mixture was allowed to stir at 40 C for 15 min with simultaneous barbotation with argon. Then a solution of 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione (1.73 g, 6.37 mmol) and 2-methylbut-3-yn-2-ol (0.93 mL, 9.56 mmol) and dry DIEA (3.6 mL) was added and stirring was continued at 50 C
for 24 h. After cooling to rt, the reaction mixture was poured to Et0Ac (300 mL), washed with brine (80 mL) containing aq. NH3 (0.5 mL) and stirred at rt for the additional min. The aqueous phase was separated and the organic phase was washed with brine (3 x 80 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel using a mixture of water (containing 0.1% HC1) - MeCN (5% - 70%) as eluent to 30 give the title compound in 42% yield. mp = 180-182 C. 1H NMR
(CDC13/TMS, 400 MHz) (ppm): 1.63 (s, 6H), 3.36 (s, 3H), 3.51 (s, 3H), 3.52 (br s, 1H), 3.90 (s, 3H).
Date Recue/Date Received 2021-07-07
15 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 28.0, 29.8, 30.8, 32.9, 65.1, 69.6, 102.5, 107.5, 135.0, 147.4, 151.5, 154.6. MS (EI) m/z: 277.2 [M+11 .
Method B. To a mixture of Pd(OAc)2 (100 mg, 0.446 mmol), CuI (169 mg, 0.868 mmol), and triphenylphosphine (233 mg, 0.890 mmol) dry NMP or DMAC (40 mL) was added. Reaction mixture was allowed to stir for 15 min at 40 C with simultaneous barbotation with argon. Then a solution of 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione (1.21 g, 4.46 mmol) and 2-methylbut-3-yn-2-ol (0.65 mL, 6.69 mmol) and dry DIEA (4.0 mL) was added and stirring was continued at 55 C
for 24 h. Compound I-1 (31% yield) was isolated as in Method A.
Method C. To a mixture of Pd(OAc)2 (100 mg, 0.446 mmol), CuI (169 mg, 0.868 mmol), and triphenylphosphine (233 mg, 0.890 mmol) dry NMP (10 mL) was added.
Reaction mixture was allowed to stir for 15 min at 40 C with simultaneous barbotation with argon. Then solution of 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,710-dione (1.21 g, 4.46 mmol) and 2-methylbut-3-yn-2-ol (0.65 mL, 6.69 mmol) and dry DIEA (4.0 mL) in NMP (10 mL) and toluene (20 mL) was added and stirring was continued at 50 C for 24 h. Compound I-1 (72% yield) was isolated as in Method A.
Method D. A vial charged with Pd(PPh3)4 (346 mg, 0.3 mmol), PdC12 (51 mg, 0.3 mmol), Ph3P (157 mg, 0.6 mmol), CuI (58 mg, 0.3 mmol), 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,71-1)-dione (4.08 g, 15.0 mmol) and 2-methylbut-3-yn-2-ol (2.05 mL, 21.0 mmol), DIEA (5.0 mL) and ethyl acetate (70 mL) was stirred for 15 min at 40 C with simultaneous barbotation with argon. Then reaction mixture was stirred for additional 2-4 h. After cooling to rt, the reaction mixture was filtered through a silica gel pad and washed with Et0Ac (200 mL). Then solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel using mixture of water (containing 0.1% aq. HC1) ¨
MeCN (5% - 70%) as eluent to give compound I-1 in 55% yield and 8-[(E)-5-hydroxy-2-(1-hydroxy-1-methylethyl)-5-methylhex-1-en-3-ynyll -1,3 ,7-tri methyl-1H-purine-2,6(3H,7H)-dione as a by-product in 26% yield. By-product: 11-1 NMR
(CDC13/TMS, 400 MHz) (ppm): 1.32 (s, 6H), 1.52 (s, 6H), 3.35 (s, 3H), 3.49 (s, 3H), Date Recue/Date Received 2021-07-07
Method B. To a mixture of Pd(OAc)2 (100 mg, 0.446 mmol), CuI (169 mg, 0.868 mmol), and triphenylphosphine (233 mg, 0.890 mmol) dry NMP or DMAC (40 mL) was added. Reaction mixture was allowed to stir for 15 min at 40 C with simultaneous barbotation with argon. Then a solution of 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione (1.21 g, 4.46 mmol) and 2-methylbut-3-yn-2-ol (0.65 mL, 6.69 mmol) and dry DIEA (4.0 mL) was added and stirring was continued at 55 C
for 24 h. Compound I-1 (31% yield) was isolated as in Method A.
Method C. To a mixture of Pd(OAc)2 (100 mg, 0.446 mmol), CuI (169 mg, 0.868 mmol), and triphenylphosphine (233 mg, 0.890 mmol) dry NMP (10 mL) was added.
Reaction mixture was allowed to stir for 15 min at 40 C with simultaneous barbotation with argon. Then solution of 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,710-dione (1.21 g, 4.46 mmol) and 2-methylbut-3-yn-2-ol (0.65 mL, 6.69 mmol) and dry DIEA (4.0 mL) in NMP (10 mL) and toluene (20 mL) was added and stirring was continued at 50 C for 24 h. Compound I-1 (72% yield) was isolated as in Method A.
Method D. A vial charged with Pd(PPh3)4 (346 mg, 0.3 mmol), PdC12 (51 mg, 0.3 mmol), Ph3P (157 mg, 0.6 mmol), CuI (58 mg, 0.3 mmol), 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,71-1)-dione (4.08 g, 15.0 mmol) and 2-methylbut-3-yn-2-ol (2.05 mL, 21.0 mmol), DIEA (5.0 mL) and ethyl acetate (70 mL) was stirred for 15 min at 40 C with simultaneous barbotation with argon. Then reaction mixture was stirred for additional 2-4 h. After cooling to rt, the reaction mixture was filtered through a silica gel pad and washed with Et0Ac (200 mL). Then solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel using mixture of water (containing 0.1% aq. HC1) ¨
MeCN (5% - 70%) as eluent to give compound I-1 in 55% yield and 8-[(E)-5-hydroxy-2-(1-hydroxy-1-methylethyl)-5-methylhex-1-en-3-ynyll -1,3 ,7-tri methyl-1H-purine-2,6(3H,7H)-dione as a by-product in 26% yield. By-product: 11-1 NMR
(CDC13/TMS, 400 MHz) (ppm): 1.32 (s, 6H), 1.52 (s, 6H), 3.35 (s, 3H), 3.49 (s, 3H), Date Recue/Date Received 2021-07-07
16 4.03 (s, 3H). 5.13 (hr s, 2H), 6.65 (s, 1H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 28.1, 29.7, 29.9, 31.0, 33.7, 65.3, 70.7, 78.6, 95.9, 107.9, 109.6, 146.5, 147.3, 151.2, 155.0, 156.1.
Example 2 8-((1-Hydroxycyclohexypethyny1)-1,3,7-trimethy1-1H-purine-2,6(3H,71/)-d lone (I-2) H
I
Yield: 49% (Method C), 54% (Method D), 11% (Method B); mp = 194-196 C. 1H
NMR (CDC13/TMS, 400 MHz) (ppm): 1.24-1.33 (m, 1H), 1.48-1.57 (m, 3H), 1.66-1.75 (m, 4H), 1.94-2.02 (m, 2H), 3.30 (hr s, 1H), 3.34 (s, 3H), 3.49 (s, 3H), 3.89 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 22.9, 24.8, 27.9, 29.7, 32.9, 39.2, 68.6, 71.5, 102.0, 107.4, 135.1, 147.3, 151.4, 154.5. MS (EI)m/z: 317.5 1M+11 .
Example 3 8-((1-Aminocyclohexypethyny1)-3,7-dimethyl-11-/-purine-2,6(3H,7H)-dione (I-3) HN )-----"N' H2% ) Yield: 48% (Method D), 43% (Method C), 16% (Method B), 7 % (Method A); mp =
187-189 C. 1H NMR (CDC13/TMS, 400 MHz) g(ppm): 1.20-1.29 (m, 1H), 1.48-1.67 (m, 5H), 1.72-1.77 (m, 2H), 1.81 (br s, 2H), 1.93-1.97 (m, 2H), 3.39 (s, 3H), 3.55 (s, 3H), 3.98 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 23.2, 25.1, 27.9, 29.7, 33.0, 39.6, 50.4, 70.9, 104.5, 107.6, 135.8, 147.6, 151.5, 154.8. MS (El) m/z:
302.3 1M+11+.
Example 4 8-(3-(Dimethylamino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,71f)-dione (I-4) Date Recue/Date Received 2021-07-07
Example 2 8-((1-Hydroxycyclohexypethyny1)-1,3,7-trimethy1-1H-purine-2,6(3H,71/)-d lone (I-2) H
I
Yield: 49% (Method C), 54% (Method D), 11% (Method B); mp = 194-196 C. 1H
NMR (CDC13/TMS, 400 MHz) (ppm): 1.24-1.33 (m, 1H), 1.48-1.57 (m, 3H), 1.66-1.75 (m, 4H), 1.94-2.02 (m, 2H), 3.30 (hr s, 1H), 3.34 (s, 3H), 3.49 (s, 3H), 3.89 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 22.9, 24.8, 27.9, 29.7, 32.9, 39.2, 68.6, 71.5, 102.0, 107.4, 135.1, 147.3, 151.4, 154.5. MS (EI)m/z: 317.5 1M+11 .
Example 3 8-((1-Aminocyclohexypethyny1)-3,7-dimethyl-11-/-purine-2,6(3H,7H)-dione (I-3) HN )-----"N' H2% ) Yield: 48% (Method D), 43% (Method C), 16% (Method B), 7 % (Method A); mp =
187-189 C. 1H NMR (CDC13/TMS, 400 MHz) g(ppm): 1.20-1.29 (m, 1H), 1.48-1.67 (m, 5H), 1.72-1.77 (m, 2H), 1.81 (br s, 2H), 1.93-1.97 (m, 2H), 3.39 (s, 3H), 3.55 (s, 3H), 3.98 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 23.2, 25.1, 27.9, 29.7, 33.0, 39.6, 50.4, 70.9, 104.5, 107.6, 135.8, 147.6, 151.5, 154.8. MS (El) m/z:
302.3 1M+11+.
Example 4 8-(3-(Dimethylamino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,71f)-dione (I-4) Date Recue/Date Received 2021-07-07
17 I ¨ __ \N¨
O N
Isolated as hydrochloride. Yield: 58% (Method D), 47% (Method C), 4% (Method B);
mp = 197-199 C (dec.) 1H NMR (DMSO-d6, 400 MHz) (ppm): 2.88 (s, 6H), 3.21 (s, 3H), 3.38 (s, 3H), 3.96 (s, 3H), 4.50 (s, 2H). 13C NMR (DMSO-d6, 100.6 MHz) (ppm): 27.6, 29.3, 33.0, 41.6, 45.7, 76.4, 87.1, 107.6, 132.9, 146.8, 150.7, 154Ø MS
(El) m/z: 277.5 [M+11.
Example 5 8-(3-(bis (2-methoxyethyl)amino)p ro p- 1-yn- 1-y1)- 1,3,7-trimethyl- 1H-p urine-2,6(3H,7H)-dione (1-5) I ¨ __ \
\-0\
Yield: 33% (Method D), 30% (Method C), 10% (Method B); foam. 1H NMR
(CDC13/TMS, 400 MHz) g(ppm): 2.79 (t, 4H), 3.31 (s, 6H), 3.34 (s, 3H), 3.48 (t, 4H), 3.51 (s, 3H), 3.82 (s, 2H), 3.96 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm):
27.8, 29.6, 33.0, 44.1, 53.5, 58.7, 70.9, 73.2, 94.1, 107.5, 135.4, 147.5, 151.4, 154.7.
MS (EI)m/z: 364.5 [M+11 .
Example 6 1,3,7-Trimethy1-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,71f)-dione (1-6) I ________________________________________ \
Yield: 57% (Method D), 52% (Method C), 8% (Method A); mp = 149-150 C. 1H
NMR (CDC13/TMS, 400 MHz) (ppm): 1.83-1.86 (m, 4H), 2.68-2.72 (m, 4H), 3.39 Date Recue/Date Received 2021-07-07
O N
Isolated as hydrochloride. Yield: 58% (Method D), 47% (Method C), 4% (Method B);
mp = 197-199 C (dec.) 1H NMR (DMSO-d6, 400 MHz) (ppm): 2.88 (s, 6H), 3.21 (s, 3H), 3.38 (s, 3H), 3.96 (s, 3H), 4.50 (s, 2H). 13C NMR (DMSO-d6, 100.6 MHz) (ppm): 27.6, 29.3, 33.0, 41.6, 45.7, 76.4, 87.1, 107.6, 132.9, 146.8, 150.7, 154Ø MS
(El) m/z: 277.5 [M+11.
Example 5 8-(3-(bis (2-methoxyethyl)amino)p ro p- 1-yn- 1-y1)- 1,3,7-trimethyl- 1H-p urine-2,6(3H,7H)-dione (1-5) I ¨ __ \
\-0\
Yield: 33% (Method D), 30% (Method C), 10% (Method B); foam. 1H NMR
(CDC13/TMS, 400 MHz) g(ppm): 2.79 (t, 4H), 3.31 (s, 6H), 3.34 (s, 3H), 3.48 (t, 4H), 3.51 (s, 3H), 3.82 (s, 2H), 3.96 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm):
27.8, 29.6, 33.0, 44.1, 53.5, 58.7, 70.9, 73.2, 94.1, 107.5, 135.4, 147.5, 151.4, 154.7.
MS (EI)m/z: 364.5 [M+11 .
Example 6 1,3,7-Trimethy1-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,71f)-dione (1-6) I ________________________________________ \
Yield: 57% (Method D), 52% (Method C), 8% (Method A); mp = 149-150 C. 1H
NMR (CDC13/TMS, 400 MHz) (ppm): 1.83-1.86 (m, 4H), 2.68-2.72 (m, 4H), 3.39 Date Recue/Date Received 2021-07-07
18 (s, 3H), 3.56 (s, 3H), 3.75 (s, 2H), 4.00 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 23.8, 27.9, 29.7, 33.1, 43.6, 52.7, 72.6, 94.5, 107.6, 135.4, 147.6, 151.5, 154.8. MS (EI)m/z: 302.3 [M+11+.
Example 7 1,3,7-Trimethy1-8-(3-(piperidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione (1-7) I ¨ __ \
Yield: 35% (Method C), 30% (Method D); mp = 137-138 C. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.40-1.48 (m, 2H), 1.60-1.67 (m, 4H), 2.54-2.60 (m, 4H), 3.39 (s, 3H), 3.55 (s, 3H), 3.60 (s, 2H), 4.00 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 23.6, 25.8, 27.9, 28.0, 29.8, 48.3, 53.4, 73.2, 94.2, 107.6, 135.5, 147.6, 151.5, 154.8. MS (EI) m/z: 316.3 [M+11+.
Example 8 8-(3-(Azepan-l-yl)prop-1-yn-l-y1)-1,3,7-trimethyl-IH-purine-2,6(3H,71/)-dione (1-8) I ________________________________________ \
Yield: 34% (Method C), foam. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.61-1.64 (m, 4H), 1.70-1.76 (m, 4H), 2.81 (t, 4H), 3.39 (s, 3H), 3.55 (s, 3H), 3.74 (s, 2H), 4.01 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) 8 (ppm): 26.6, 27.9, 28.0, 29.7, 33.1, 48.7, 55.3, 72.9, 93.2, 107.6, 135.4, 147.6, 151.5, 154.8. MS (EI)m/z: 330.3 [M+11 .
Example 9 Date Recue/Date Received 2021-07-07
Example 7 1,3,7-Trimethy1-8-(3-(piperidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione (1-7) I ¨ __ \
Yield: 35% (Method C), 30% (Method D); mp = 137-138 C. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.40-1.48 (m, 2H), 1.60-1.67 (m, 4H), 2.54-2.60 (m, 4H), 3.39 (s, 3H), 3.55 (s, 3H), 3.60 (s, 2H), 4.00 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 23.6, 25.8, 27.9, 28.0, 29.8, 48.3, 53.4, 73.2, 94.2, 107.6, 135.5, 147.6, 151.5, 154.8. MS (EI) m/z: 316.3 [M+11+.
Example 8 8-(3-(Azepan-l-yl)prop-1-yn-l-y1)-1,3,7-trimethyl-IH-purine-2,6(3H,71/)-dione (1-8) I ________________________________________ \
Yield: 34% (Method C), foam. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.61-1.64 (m, 4H), 1.70-1.76 (m, 4H), 2.81 (t, 4H), 3.39 (s, 3H), 3.55 (s, 3H), 3.74 (s, 2H), 4.01 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) 8 (ppm): 26.6, 27.9, 28.0, 29.7, 33.1, 48.7, 55.3, 72.9, 93.2, 107.6, 135.4, 147.6, 151.5, 154.8. MS (EI)m/z: 330.3 [M+11 .
Example 9 Date Recue/Date Received 2021-07-07
19 1,3,7-Trimethy1-8-(3-morpholinoprop-1-yn-1-y1)-1H-purine-2,6(3H,71/)-d lone (I-9) NN
=
ONN
Yield: 38% (Method C), mp =188-190 C. 11-1 NMR (CDC13/TMS, 400 MHz) (ppm): 2.64 (t, 4H), 3.40 (s, 3H), 3.56 (s, 3H), 3.64 (s, 2H), 3.76 (t, 4H), 4.01 (s, 3H).
13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 28.0, 29.7, 33.2, 47.8, 52.3, 66.7, 73.7, 93.1, 107.7, 135.2, 147.6, 151.5, 154.8. MS (0) m/z: 318.3 [M+11 .
Example 10 8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione (I-10) OH
=
ONN
Yield: 47% (Method D), 44% (Method C); foam. 1H NMR (CDC13/TMS, 400 MHz) c5 (ppm): 1.62-1.66 (m, 4H), 1.65 (s, 6H), 2.12 (s, 3H), 2.48 (t, 2H), 2.72 (hr s, 1H), 3.53 (s, 3H), 3.96 (s, 3H), 3.97 (t, 2H). 13C NMR (CDC13/TMS, 100.6 MHz) g(ppm):
=
ONN
Yield: 38% (Method C), mp =188-190 C. 11-1 NMR (CDC13/TMS, 400 MHz) (ppm): 2.64 (t, 4H), 3.40 (s, 3H), 3.56 (s, 3H), 3.64 (s, 2H), 3.76 (t, 4H), 4.01 (s, 3H).
13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 28.0, 29.7, 33.2, 47.8, 52.3, 66.7, 73.7, 93.1, 107.7, 135.2, 147.6, 151.5, 154.8. MS (0) m/z: 318.3 [M+11 .
Example 10 8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione (I-10) OH
=
ONN
Yield: 47% (Method D), 44% (Method C); foam. 1H NMR (CDC13/TMS, 400 MHz) c5 (ppm): 1.62-1.66 (m, 4H), 1.65 (s, 6H), 2.12 (s, 3H), 2.48 (t, 2H), 2.72 (hr s, 1H), 3.53 (s, 3H), 3.96 (s, 3H), 3.97 (t, 2H). 13C NMR (CDC13/TMS, 100.6 MHz) g(ppm):
20.9, 27.3, 29.7, 29.9, 30.9, 33.0, 40.9, 43.1, 65.4, 70.0, 102.2, 107.7, 135.1, 147.6, 151.2, 154.6, 208.7. MS (0) inlz: 361.1 [M+11 .
Example 11 8-((1-Hydroxycyclohexypethyny1)-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione (I-11) )N)=_.,_1\1 HO
I ¨
CN
N
Yield: 42% (Method C), mp = 126-128 C. 11-1 NMR (CDC13/TMS, 400 MHz) (ppm): 1.27-1.37 (m, 1H), 1.54-1.79 (m, 7H), 2.02-2.08 (m, 2H), 2.13 (s, 3H), 2.48 (t, 2H), 3.54 (s, 3H), 3.97 (s, 3H), 3.97-4.01 (2H, m). 13C NMR (CDC13/TMS, 100.6 Date Recue/Date Received 2021-07-07 MHz) (ppm): 20.9, 23.0, 24.9, 27.4, 29.7, 29.9, 33.1, 39.3, 40.9, 43.1, 69.0, 72.0, 101.5, 107.8, 135.3, 147.6, 151.2, 154.6, 208.6. MS (El) m/z: 401.6 [M+11 .
Example 12 8-((1-Aminocyclohexypethyny1)-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione (1-12) )LNN H2N
¨
N N
Yield: 45% (Method C), mp > 200 C. 1H NMR (CDC13/TMS, 400 MHz) 8 (ppm):
1.24-1.34 (m, 1H), 1.61-1.84 (m, 7H), 1.95-2.01 (m, 2H), 2.13 (s, 3H), 2.34-2.37 (m, 2H), 2.48 (t, 2H), 3.39 (s, 3H), 3.49 (s, 3H, 3.93-3.97 (m, 2H), 4.01 (s, 3H), 9.28 (br s, 2H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 20.9, 22.5, 24.1, 27.3, 25.1, 29.7, 29.9, 33.5, 35.9, 41.0, 43.1, 53.6, 75.7, 93.9, 108.0, 133.8, 147.4, 150.9, 154.4, 208.6.
MS (0) m/z: 400.5 [M+11 .
Example 13 8-(3-(Bis(2-methoxyethyDamino)prop-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,71/)-dione (1-13) )N
0 N N N¨\
\-0 Yield: 35% (Method C), foam. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.60-1.65 (m, 4H), 2.10 (s, 3H), 2.47 (t, 2H), 2.34-2.37 (m, 2H), 2.83 (t, 4H), 3.30 (s, 6H), 3.45 (t, 4H), 3.54-3.55 (m, 2H), 3.56 (s, 3H), 3.92 (s, 3H), 3.97 (t, 2H). 13C NMR
(CDC13/TMS, 100.6 MHz) g(ppm): 20.9, 27.4, 29.8, 31.9, 40.7, 43.1, 54.2, 58.8, 63.0, 66.5, 71.0, 76.9, 107.2, 110.3, 143.1, 147.3, 148A, 151.3, 155.1, 208.6. MS
(0) m/z:
448.6 [M+11 .
Example 14 Date Recue/Date Received 2021-07-07
Example 11 8-((1-Hydroxycyclohexypethyny1)-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione (I-11) )N)=_.,_1\1 HO
I ¨
CN
N
Yield: 42% (Method C), mp = 126-128 C. 11-1 NMR (CDC13/TMS, 400 MHz) (ppm): 1.27-1.37 (m, 1H), 1.54-1.79 (m, 7H), 2.02-2.08 (m, 2H), 2.13 (s, 3H), 2.48 (t, 2H), 3.54 (s, 3H), 3.97 (s, 3H), 3.97-4.01 (2H, m). 13C NMR (CDC13/TMS, 100.6 Date Recue/Date Received 2021-07-07 MHz) (ppm): 20.9, 23.0, 24.9, 27.4, 29.7, 29.9, 33.1, 39.3, 40.9, 43.1, 69.0, 72.0, 101.5, 107.8, 135.3, 147.6, 151.2, 154.6, 208.6. MS (El) m/z: 401.6 [M+11 .
Example 12 8-((1-Aminocyclohexypethyny1)-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione (1-12) )LNN H2N
¨
N N
Yield: 45% (Method C), mp > 200 C. 1H NMR (CDC13/TMS, 400 MHz) 8 (ppm):
1.24-1.34 (m, 1H), 1.61-1.84 (m, 7H), 1.95-2.01 (m, 2H), 2.13 (s, 3H), 2.34-2.37 (m, 2H), 2.48 (t, 2H), 3.39 (s, 3H), 3.49 (s, 3H, 3.93-3.97 (m, 2H), 4.01 (s, 3H), 9.28 (br s, 2H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 20.9, 22.5, 24.1, 27.3, 25.1, 29.7, 29.9, 33.5, 35.9, 41.0, 43.1, 53.6, 75.7, 93.9, 108.0, 133.8, 147.4, 150.9, 154.4, 208.6.
MS (0) m/z: 400.5 [M+11 .
Example 13 8-(3-(Bis(2-methoxyethyDamino)prop-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,71/)-dione (1-13) )N
0 N N N¨\
\-0 Yield: 35% (Method C), foam. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.60-1.65 (m, 4H), 2.10 (s, 3H), 2.47 (t, 2H), 2.34-2.37 (m, 2H), 2.83 (t, 4H), 3.30 (s, 6H), 3.45 (t, 4H), 3.54-3.55 (m, 2H), 3.56 (s, 3H), 3.92 (s, 3H), 3.97 (t, 2H). 13C NMR
(CDC13/TMS, 100.6 MHz) g(ppm): 20.9, 27.4, 29.8, 31.9, 40.7, 43.1, 54.2, 58.8, 63.0, 66.5, 71.0, 76.9, 107.2, 110.3, 143.1, 147.3, 148A, 151.3, 155.1, 208.6. MS
(0) m/z:
448.6 [M+11 .
Example 14 Date Recue/Date Received 2021-07-07
21 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(pyrrolidin-1-yDp ro p-1-yn-l-y1)-1H- pu rine-2,6(3H,7H)-dione (1-14) I
0 N.--1\1 Isolated as hydrochloride. Yield: 41%, foam. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.61-1.70 (m, 4H), 1.82-1.86 (m, 4H), 2.13 (s, 3H), 2.49 (t, 2H), 2.64-2.68 (m, 4H), 3.48 (d, 2H), 3.58 (s, 3H), 3.93 (s, 3H), 4.01 (t, 2H), 6.78 (hr s, 1H).
(CDC13/TMS, 100.6 MHz) g(ppm): 20.8, 23.9, 27.3, 29.6, 29.9, 33.6, 40.9, 43.0, 43.3, 52.7, 77.6, 85.1, 108.4, 133.0, 147.4, 151.0, 154.5. 208.5. MS (EI)m/z: 386.3 [M+11 .
Example 15 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(piperidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione (1-15) ______________________________________________ \N
Yield: 39% (Method C), mp = 182-184 C. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.34-1.48 (m, 1H), 1.58-1.66 (m, 4H), 1.90-1.93 (m, 3H), 2.11 (s, 3H), 2.21-2.29 (m, 2H), 2.47 (t, 2H), 2.94-2.97 (m, 2H), 3.51 (s, 3H), 3.60-3.63 (m, 2H), 3.97 (t, 2H), 4.07 (s, 3H), 4.22 (s, 2H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 20.8, 21.5, 22.7, 27.3, 29.6, 29.9, 33.7, 40.9, 43.0, 46.7, 52.6, 78.7, 84.6, 108.5, 133.1, 147.5, 151.0, 154.5, 208.5. MS (EI)in/z: 400.2 [M+11 .
Example 16 1,3,7-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,7H)-dione (1-16) NN
Date Recue/Date Received 2021-07-07
0 N.--1\1 Isolated as hydrochloride. Yield: 41%, foam. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.61-1.70 (m, 4H), 1.82-1.86 (m, 4H), 2.13 (s, 3H), 2.49 (t, 2H), 2.64-2.68 (m, 4H), 3.48 (d, 2H), 3.58 (s, 3H), 3.93 (s, 3H), 4.01 (t, 2H), 6.78 (hr s, 1H).
(CDC13/TMS, 100.6 MHz) g(ppm): 20.8, 23.9, 27.3, 29.6, 29.9, 33.6, 40.9, 43.0, 43.3, 52.7, 77.6, 85.1, 108.4, 133.0, 147.4, 151.0, 154.5. 208.5. MS (EI)m/z: 386.3 [M+11 .
Example 15 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(piperidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione (1-15) ______________________________________________ \N
Yield: 39% (Method C), mp = 182-184 C. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.34-1.48 (m, 1H), 1.58-1.66 (m, 4H), 1.90-1.93 (m, 3H), 2.11 (s, 3H), 2.21-2.29 (m, 2H), 2.47 (t, 2H), 2.94-2.97 (m, 2H), 3.51 (s, 3H), 3.60-3.63 (m, 2H), 3.97 (t, 2H), 4.07 (s, 3H), 4.22 (s, 2H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 20.8, 21.5, 22.7, 27.3, 29.6, 29.9, 33.7, 40.9, 43.0, 46.7, 52.6, 78.7, 84.6, 108.5, 133.1, 147.5, 151.0, 154.5, 208.5. MS (EI)in/z: 400.2 [M+11 .
Example 16 1,3,7-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,7H)-dione (1-16) NN
Date Recue/Date Received 2021-07-07
22 1H NMR (CDC13/TMS, 400 MHz) 8 (ppm): Yield: 36% (Method C). 1H NMR
(CDC13/TMS, 400 MHz) (ppm): 3.43 (s, 3H), 3.61 (s, 3H), 4.10 (s, 3H), 7.39-7.46 (m, 3H), 7.61-7.63 (m, 2H). MS (EI) m/z: 295.5 [Mr Example 17 1,3,9-Trimethy1-8-(3-(pyrrolidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,911)-dione (I-17) \
Isolated as hydrochloride. 1H NMR (DMSO-d6, 400 MHz) 8 (ppm): 1.86-1.99 (m, 4H), 3.07-3.20 (m, 4H), 3.25 (s, 3H), 3.72 (s, 3H), 3.93 (s, 3H), 4.35 (s, 2H). MS (El) m/z: 302.1 [Mr Example 18 1,3,9-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,9H)-dione (I-18) _________________________________________ ( I \
Yield: 75% (Method C), mp > 200 C. 1H NMR (CDC13/TMS, 400 MHz) 8 (ppm):
3.42 (s, 3H), 3.80 (s, 3H), 4.06 (s, 3H), 7.35-7.42 (m, 3H), 7.53-7.55 (m, 2H).
13C NMR (DMSO-d6, 100.6 MHz) g (ppm): 28.1, 31.0, 33.8, 78.1, 93.6, 116.6, 120.1, 128.9, 129.9, 131.2, 131.6, 140.0, 150.8, 156.1. MS (EI) m/z: 295.3 [Mr.
ANTIPROLIFERATIVE ACTIVITY
Anticancer activity of 8-ethynylxanthines was tested on monolayer tumor cell lines:
MDA-MB-435s (human melanoma), H9C2 (rat embrio cardiomyoblast), MCF-7 (human breast adenocarcinoma, estrogen-positive), HepG2 (human hepatocellular carcinoma), SH-SY5Y (human neuroblastoma), C6 (rat glioma), U937 (human histiocytic leukemia), and A549 (human lung carcinoma). The borderline concentration, relevant to the highest tolerated dose, was determined for each Date Recue/Date Received 2021-07-07
(CDC13/TMS, 400 MHz) (ppm): 3.43 (s, 3H), 3.61 (s, 3H), 4.10 (s, 3H), 7.39-7.46 (m, 3H), 7.61-7.63 (m, 2H). MS (EI) m/z: 295.5 [Mr Example 17 1,3,9-Trimethy1-8-(3-(pyrrolidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,911)-dione (I-17) \
Isolated as hydrochloride. 1H NMR (DMSO-d6, 400 MHz) 8 (ppm): 1.86-1.99 (m, 4H), 3.07-3.20 (m, 4H), 3.25 (s, 3H), 3.72 (s, 3H), 3.93 (s, 3H), 4.35 (s, 2H). MS (El) m/z: 302.1 [Mr Example 18 1,3,9-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,9H)-dione (I-18) _________________________________________ ( I \
Yield: 75% (Method C), mp > 200 C. 1H NMR (CDC13/TMS, 400 MHz) 8 (ppm):
3.42 (s, 3H), 3.80 (s, 3H), 4.06 (s, 3H), 7.35-7.42 (m, 3H), 7.53-7.55 (m, 2H).
13C NMR (DMSO-d6, 100.6 MHz) g (ppm): 28.1, 31.0, 33.8, 78.1, 93.6, 116.6, 120.1, 128.9, 129.9, 131.2, 131.6, 140.0, 150.8, 156.1. MS (EI) m/z: 295.3 [Mr.
ANTIPROLIFERATIVE ACTIVITY
Anticancer activity of 8-ethynylxanthines was tested on monolayer tumor cell lines:
MDA-MB-435s (human melanoma), H9C2 (rat embrio cardiomyoblast), MCF-7 (human breast adenocarcinoma, estrogen-positive), HepG2 (human hepatocellular carcinoma), SH-SY5Y (human neuroblastoma), C6 (rat glioma), U937 (human histiocytic leukemia), and A549 (human lung carcinoma). The borderline concentration, relevant to the highest tolerated dose, was determined for each Date Recue/Date Received 2021-07-07
23 compound using the NIH 3T3 (Mouse Swiss Albino embryo fibroblasts) cell line.
The basal cytotoxicity was used to predict starting doses for in vivo acute oral LD50 values in rodent. The results of these experiments are summarized in Table 1.
Caffeine, Proxyfeine, Pentoxifylline and Temodar were used as references. Caffeine and Pentoxifylline exhibit no cytotoxic effect on all studied cell lines. Despite the fact that Temodar is widely used drug for brain cancer prevention, in vitro results showed more than a modest activity on studied tumor cell lines (IC50=298 [IM on SH-neuroblastoma and IC50=31 [iM on U937 lymphoma cell lines). Cancer cells are more sensitive to Proxyfeine (IC50=96-283 [iM). Surprisingly, 8-ethynylcaffeines have an extended ability to suppress cancer cell growth. Thus, caffeine derivatives 1-showed high in vitro antiproliferative effect against majority of cancer cells, moreover, these compounds are active against brain tumors (IC50=8.2 11.5 [iM on SH-SY5Y
and C6 cell lines). It should be noted that caffeine 1-3 selectively inhibits lymphoma U937 cell growth (IC50=5.1 HM), and derivative 1-6 ¨ estrogen-positive human breast adenocarcinoma MCF-7 (IC50=5.7 [iM). In a series of pentoxifylline derivatives 15 piperidylmethyl derivative 1-15 showed high cytotoxicity against studied cancer cells, especially, on lymphoma U937 (IC50=4.7 M) and glioma C6 (IC50=7.1 [iM).
In vitro cytotoxicity assay Monolayer tumor cell line: MDA-MB-435s (human melanoma), H9C2 (rat embrio cardiomyoblast), MCF-7 (human breast adenocarcinoma, estrogen-positive), HepG2 (human hepatocellular carcinoma), SH-SY5Y (human neuroblastoma), C6 (rat glioma), U937 (human histiocytic leukemia), and A549 (human lung carcinoma), and normal cell line NIH 3T3 (mouse fibroblasts) were cultured in standard medium DMEM (Dulbecco's modified Eagle's medium) containing 1% non-essential amino-acids, 2 mM glutamine and supplemented with 10% fetal bovine serum (FBS, Sigma) ("Sigma"). All cells obtained from the American Type Culture Collection.
About 2-10.104 cells/mL (depending on line nature) were placed in 96-well plates immediately after compounds were added to the wells. The control cells without test compounds were cultured on separate plate. The plates were incubated for 72 h, C, 5% CO2. The number of surviving cells was determined using 344,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolinium bromide (MTT). MTT-test: after incubating with preparations culture medium was removed and 200 [it of fresh Date Recue/Date Received 2021-07-07
The basal cytotoxicity was used to predict starting doses for in vivo acute oral LD50 values in rodent. The results of these experiments are summarized in Table 1.
Caffeine, Proxyfeine, Pentoxifylline and Temodar were used as references. Caffeine and Pentoxifylline exhibit no cytotoxic effect on all studied cell lines. Despite the fact that Temodar is widely used drug for brain cancer prevention, in vitro results showed more than a modest activity on studied tumor cell lines (IC50=298 [IM on SH-neuroblastoma and IC50=31 [iM on U937 lymphoma cell lines). Cancer cells are more sensitive to Proxyfeine (IC50=96-283 [iM). Surprisingly, 8-ethynylcaffeines have an extended ability to suppress cancer cell growth. Thus, caffeine derivatives 1-showed high in vitro antiproliferative effect against majority of cancer cells, moreover, these compounds are active against brain tumors (IC50=8.2 11.5 [iM on SH-SY5Y
and C6 cell lines). It should be noted that caffeine 1-3 selectively inhibits lymphoma U937 cell growth (IC50=5.1 HM), and derivative 1-6 ¨ estrogen-positive human breast adenocarcinoma MCF-7 (IC50=5.7 [iM). In a series of pentoxifylline derivatives 15 piperidylmethyl derivative 1-15 showed high cytotoxicity against studied cancer cells, especially, on lymphoma U937 (IC50=4.7 M) and glioma C6 (IC50=7.1 [iM).
In vitro cytotoxicity assay Monolayer tumor cell line: MDA-MB-435s (human melanoma), H9C2 (rat embrio cardiomyoblast), MCF-7 (human breast adenocarcinoma, estrogen-positive), HepG2 (human hepatocellular carcinoma), SH-SY5Y (human neuroblastoma), C6 (rat glioma), U937 (human histiocytic leukemia), and A549 (human lung carcinoma), and normal cell line NIH 3T3 (mouse fibroblasts) were cultured in standard medium DMEM (Dulbecco's modified Eagle's medium) containing 1% non-essential amino-acids, 2 mM glutamine and supplemented with 10% fetal bovine serum (FBS, Sigma) ("Sigma"). All cells obtained from the American Type Culture Collection.
About 2-10.104 cells/mL (depending on line nature) were placed in 96-well plates immediately after compounds were added to the wells. The control cells without test compounds were cultured on separate plate. The plates were incubated for 72 h, C, 5% CO2. The number of surviving cells was determined using 344,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolinium bromide (MTT). MTT-test: after incubating with preparations culture medium was removed and 200 [it of fresh Date Recue/Date Received 2021-07-07
24 medium with 10 mM HEPES was added in each well of the plate, then 20 [it of MTT (2 mg/mL in HBSS) was added. After incubation (3 h., 37 C, 5%CO2) the medium with MTT was removed and 200 [it of DMSO and 25 [it of glycine buffer (pH 10.5) were added at once to each sample. The samples were tested at 540 nm on Anthos HT II photometer.
Basal toxicity test Compounds were tested on NIH 3T3 (normal mouse fibroblasts, "ATCC") cell line according the basal toxicity test (INVITOX Protocol No 64, 1992) and non-toxic compounds were selected. 9,000 NIH 3T3 cells/well were placed into 96-well plates for 24 h and then exposed to the test compound over a range of eight concentration (1-1000 ng/mL) for 24 h. Upon that, the cells were incubated with the neutral red dye for 4 h and then OD was determined at 540 nm. Alternative LD50 values (LD50 value is the amount of the drug that is taken to kill 50% of the test animals) was calculated according to the formula: log (LD50 [mmol/kg] = 0.435 x log (IC50 Immo1/11) =
0.625.
The IC50 values were calculated using the program Graph Pad 5 Prism 3Ø
Date Recue/Date Received 2021-07-07 o o) (T
x CD
K-) c a) 0 Table 1. In vitro cytotoxicity caused by 8-ethynylxanthines was tested on monolayer tumor cell lines: MDA-MB-435s (human melanoma), m .6 x H9C2 (rat embrio cardiomyoblast), MCF-7 (human breast adenocarcinoma, estrogen-positive), HepG2 (human hepatocellular carcinoma), SH-m m . SY5Y (human neuroblastoma), C6 (rat glioma), U937 (human histiocytic leukemia), and A549 (human lung carcinoma).
m 0.
N., N., 0 MDA-MB-435s 119C2 MCF-7 HepG2 SH-SY5Y C6 -.-, 0 Compound -.., ICso ICso ICso ICso IC50 IC50 IC50 IC50 1_,D50, mg/kg Caffeine * * * * * *
* * 1670 Proxyfeine 283 * 135 * 111 96 97 * 1891 Pentoxifylline * * * * * *
* * >2000 Temodar 515 * * * 298 *
31 * >2000 t.) I-1 119 141 * * 83 261 79 239 1116 t.it 1-2 * * * * * 187 95 * 1329 5.1 52 347 9.2 42 873 1-5 * * * * * *
* * 1924 1-6 8.6 75 5.7 17 8.6 11.5 26 8.6 262 1-7 14 68 14 60 14 8.5 5.7 17 383 1-8 8.2 8.2 8.2 13.7 8.2 8.2 5.5 8.2 287 1-9 * * * * * *
124 * 1676 1-10 * 22 169 86 105 277 I-11 * * 259 * 116 183 o o) (T
x CD
K-) c a) o 1-12 80 46 73 96 64 sm g 1-14 7.3 9.8 4.9 12 4.9 17 12 7.3 253 x m m 1-15 19 52 11.8 26 9.5 7.1 4.7 11.8 698 m 0.
13.6 85 648 r..) r..) 1-17 * * * * 193 *
151 * 1733 -.-, -.., aIC50 - Concentration (pM) providing 50% cell killing effect (MTT).
t\.) ca,
Basal toxicity test Compounds were tested on NIH 3T3 (normal mouse fibroblasts, "ATCC") cell line according the basal toxicity test (INVITOX Protocol No 64, 1992) and non-toxic compounds were selected. 9,000 NIH 3T3 cells/well were placed into 96-well plates for 24 h and then exposed to the test compound over a range of eight concentration (1-1000 ng/mL) for 24 h. Upon that, the cells were incubated with the neutral red dye for 4 h and then OD was determined at 540 nm. Alternative LD50 values (LD50 value is the amount of the drug that is taken to kill 50% of the test animals) was calculated according to the formula: log (LD50 [mmol/kg] = 0.435 x log (IC50 Immo1/11) =
0.625.
The IC50 values were calculated using the program Graph Pad 5 Prism 3Ø
Date Recue/Date Received 2021-07-07 o o) (T
x CD
K-) c a) 0 Table 1. In vitro cytotoxicity caused by 8-ethynylxanthines was tested on monolayer tumor cell lines: MDA-MB-435s (human melanoma), m .6 x H9C2 (rat embrio cardiomyoblast), MCF-7 (human breast adenocarcinoma, estrogen-positive), HepG2 (human hepatocellular carcinoma), SH-m m . SY5Y (human neuroblastoma), C6 (rat glioma), U937 (human histiocytic leukemia), and A549 (human lung carcinoma).
m 0.
N., N., 0 MDA-MB-435s 119C2 MCF-7 HepG2 SH-SY5Y C6 -.-, 0 Compound -.., ICso ICso ICso ICso IC50 IC50 IC50 IC50 1_,D50, mg/kg Caffeine * * * * * *
* * 1670 Proxyfeine 283 * 135 * 111 96 97 * 1891 Pentoxifylline * * * * * *
* * >2000 Temodar 515 * * * 298 *
31 * >2000 t.) I-1 119 141 * * 83 261 79 239 1116 t.it 1-2 * * * * * 187 95 * 1329 5.1 52 347 9.2 42 873 1-5 * * * * * *
* * 1924 1-6 8.6 75 5.7 17 8.6 11.5 26 8.6 262 1-7 14 68 14 60 14 8.5 5.7 17 383 1-8 8.2 8.2 8.2 13.7 8.2 8.2 5.5 8.2 287 1-9 * * * * * *
124 * 1676 1-10 * 22 169 86 105 277 I-11 * * 259 * 116 183 o o) (T
x CD
K-) c a) o 1-12 80 46 73 96 64 sm g 1-14 7.3 9.8 4.9 12 4.9 17 12 7.3 253 x m m 1-15 19 52 11.8 26 9.5 7.1 4.7 11.8 698 m 0.
13.6 85 648 r..) r..) 1-17 * * * * 193 *
151 * 1733 -.-, -.., aIC50 - Concentration (pM) providing 50% cell killing effect (MTT).
t\.) ca,
Claims (12)
1. A compound selected from those of Formula I:
R1 Nv R3 ¨ ______________________________________________ R4 ON
wherein R1 represents hydrogen, Cl_4alkyl, hydroxy-C2_4a1ky1, Cl_3alkoxy-C2_4alkyl, Ci-3alkylcarbonyl-C1_4alkyl or C1_3alkyl(Ci_3alkyl)amino-C2_4alkyl;
R2 represents C1-4alkyl, hydroxy-C2-4alkyl, Ci_4alkylcarbonyl-C1-4alkyl, Ci-3alkoxy-C2-4alkyl, C1-3alkyl(C1-3alkyl)amino-C2-4alkyl or halo-C2_4alkyl;
R3 represents Ci_4a1ky1, allyl or Ci_3a1koxy-C2_4a1ky1;
R4 represents Ci_4a1ky1, hydroxy-C1_4a1ky1, Ci_3a1koxy-C1-4alkyl, amino-C1_4alkyl, 1-hydroxy-di-(Ci -3 alkyl)methyl, 1-amino-di-(C1_3alkyOmethyl, 1-hydroxy-cyclo-6alky1, 1-amino-cyclo-C3_6alkyl, 1-(hydroxy-C1-3alkyl)-cyc1oC3-6alkyl, Ci-3alkylamino-C1-3a1ky1, C1_3alkyl(C1_3alkyl)amino-C1_3alkyl, di-(C1_3alkoxy-C2_4a1ky1)-amino-C1-3alkyl, heterocyclyl-C1_3alkyl, aryl or heteroaryl;
with the proviso that if R2 is ethyl, R3 is methyl and R4 is 1-hydroxy-ethyl, then Ri is not a hydrogen;
with the proviso that if substituent R3 is at purine N(7) atom the dotted line between N(7) and C(8) represents no bond, and the dotted line between C(8) and N(9) represents chemical bond;
and Date Recue/Date Received 2021-07-07 with the proviso that if substituent R3 is at purine N(9) atom the dotted line between N(7) and C(8) represents chemical bond, and the dotted line between C(8) and N(9) represents no bond;
wherein the term "heterocycly1" represents saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heterocyclyl is one of azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl;
the term "aryl" represents phenyl or phenyl substituted by one or more substituents selected independently from halogen, cyano, C 1-4 al koxy carbonyl, N-C 1-4alkylaminocarbonyl, N,N-di-(Cl_3alkyl)aminocarbonyl, CH2OH, trifluoromethyl, CI_ allyl, C2_4a1kyny1, C1_4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6a1koxy, hydroxy-Cl_4alkyl, Cl_3a1koxy-C1_4alky1, C1-3 alkoxy-C2_4a1koxy, di-(Ci-3 alkyl)amino, di-(C1_3alky1)amino-C1_3 alkyl, di-(C
1_3 alkyl)amino-C2_4alkoxy, Cl_4alkylsulfonylamino and Ci-4a1ky1-aminosulfonyl;
the term "heteroaryl" represents an aromatic 5 or 6 membered ring comprising one to three heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl is unsubstituted or is substituted by one or more substituents selected independently from halogen, cyano, trifluoromethyl, C1_4alkyl, C1_4alk0xy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alk0xy, C1-3 alkoxy-C1_4alkyl, cyclo-C3_6alkylamino and di-(C1_3alkyl)amino;
its optical isomers, and pharmaceutically acceptable acid addition salts and hydrates and solvates thereof with the proviso that 8-(3-hydroxyprop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione is excluded.
R1 Nv R3 ¨ ______________________________________________ R4 ON
wherein R1 represents hydrogen, Cl_4alkyl, hydroxy-C2_4a1ky1, Cl_3alkoxy-C2_4alkyl, Ci-3alkylcarbonyl-C1_4alkyl or C1_3alkyl(Ci_3alkyl)amino-C2_4alkyl;
R2 represents C1-4alkyl, hydroxy-C2-4alkyl, Ci_4alkylcarbonyl-C1-4alkyl, Ci-3alkoxy-C2-4alkyl, C1-3alkyl(C1-3alkyl)amino-C2-4alkyl or halo-C2_4alkyl;
R3 represents Ci_4a1ky1, allyl or Ci_3a1koxy-C2_4a1ky1;
R4 represents Ci_4a1ky1, hydroxy-C1_4a1ky1, Ci_3a1koxy-C1-4alkyl, amino-C1_4alkyl, 1-hydroxy-di-(Ci -3 alkyl)methyl, 1-amino-di-(C1_3alkyOmethyl, 1-hydroxy-cyclo-6alky1, 1-amino-cyclo-C3_6alkyl, 1-(hydroxy-C1-3alkyl)-cyc1oC3-6alkyl, Ci-3alkylamino-C1-3a1ky1, C1_3alkyl(C1_3alkyl)amino-C1_3alkyl, di-(C1_3alkoxy-C2_4a1ky1)-amino-C1-3alkyl, heterocyclyl-C1_3alkyl, aryl or heteroaryl;
with the proviso that if R2 is ethyl, R3 is methyl and R4 is 1-hydroxy-ethyl, then Ri is not a hydrogen;
with the proviso that if substituent R3 is at purine N(7) atom the dotted line between N(7) and C(8) represents no bond, and the dotted line between C(8) and N(9) represents chemical bond;
and Date Recue/Date Received 2021-07-07 with the proviso that if substituent R3 is at purine N(9) atom the dotted line between N(7) and C(8) represents chemical bond, and the dotted line between C(8) and N(9) represents no bond;
wherein the term "heterocycly1" represents saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heterocyclyl is one of azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl;
the term "aryl" represents phenyl or phenyl substituted by one or more substituents selected independently from halogen, cyano, C 1-4 al koxy carbonyl, N-C 1-4alkylaminocarbonyl, N,N-di-(Cl_3alkyl)aminocarbonyl, CH2OH, trifluoromethyl, CI_ allyl, C2_4a1kyny1, C1_4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6a1koxy, hydroxy-Cl_4alkyl, Cl_3a1koxy-C1_4alky1, C1-3 alkoxy-C2_4a1koxy, di-(Ci-3 alkyl)amino, di-(C1_3alky1)amino-C1_3 alkyl, di-(C
1_3 alkyl)amino-C2_4alkoxy, Cl_4alkylsulfonylamino and Ci-4a1ky1-aminosulfonyl;
the term "heteroaryl" represents an aromatic 5 or 6 membered ring comprising one to three heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl is unsubstituted or is substituted by one or more substituents selected independently from halogen, cyano, trifluoromethyl, C1_4alkyl, C1_4alk0xy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alk0xy, C1-3 alkoxy-C1_4alkyl, cyclo-C3_6alkylamino and di-(C1_3alkyl)amino;
its optical isomers, and pharmaceutically acceptable acid addition salts and hydrates and solvates thereof with the proviso that 8-(3-hydroxyprop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione is excluded.
2. The compound as claimed in Claim 1, wherein R3 is at purine N(7) atom.
3. The compound as claimed in Claim 1, wherein R3 is at purine N(9) atom.
4. The compound as claimed in any one of Claims 1, 2 and 3, wherein R4 represents hydroxy-Ci_4alkyl, amino-C1_4alky1, 1-hydroxy-di-(C1_3alkyl)methyl, 1 -amino-di-(C 1-3 al kyl)methyl, 1 -hy droxy-cy cl o-C3_6 alkyl, 1 -amino-cy cl o-C3-Date Recue/Date Received 2021-07-07 6alkyl, 1-(hydroxy-Cl_3alkyl)-cyc1oC3_6a1ky1, C1-3alkyl(C1-3alkyl)amino-C1-3alkyl, di-(C1_3alkoxy-C2_4alkyl)-amino-Ci_3alkyl, heterocyclyl-C1-3alkyl or aryl.
5. The compound as claimed in Claim 4, wherein R2 and R3 each independently represent Ci_4a1ky1 or C1-3alkoxy-C2-4alkyl with the proviso that if R2 is ethyl, R3 is methyl and R4 is 1-hydroxy-ethyl, then RI is not a hydrogen.
6. The compound as claimed in Claim 5, wherein R2 and R3 each represent methyl.
7. The compound as claimed in any one of Claims 1 to 6, wherein R1 represents methyl or 5-oxohexyl.
8. The compound as claimed in Claim 1, which is selected from:
8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexyl)ethyny1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione, 8-(3-(Dimethylamino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-(3-(bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-(pyrrolidin-1-y0prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-(piperidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 8-(3-(Azepan-1-yl)prop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-morpholinoprop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexyl)ethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, Date Recue/Date Received 2021-07-07 8-(3-(Bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(piperidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,7H)-dione, 1,3,9-Trimethy1-8-(3-(pyrrolidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,9H)-dione, and 1,3,9-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,9H)-dione and optical isomers, and pharmaceutically-acceptable acid addition salts, hydrates, and solvates thereof
8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexyl)ethyny1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione, 8-(3-(Dimethylamino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-(3-(bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-(pyrrolidin-1-y0prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-(piperidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 8-(3-(Azepan-1-yl)prop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-morpholinoprop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexyl)ethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, Date Recue/Date Received 2021-07-07 8-(3-(Bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(piperidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,7H)-dione, 1,3,9-Trimethy1-8-(3-(pyrrolidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,9H)-dione, and 1,3,9-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,9H)-dione and optical isomers, and pharmaceutically-acceptable acid addition salts, hydrates, and solvates thereof
9. The compound as claimed in any one of Claims 1 to 8 for use in the treatment or prevention of melanoma, breast adenocarcinoma, hepatocellular carcinoma, neuroblastoma, glioma, lymphoma, or lung cancer.
10. A process for the synthesis of a compound selected from those of Formula I:
R1 it N/R3 -W
j l ___________________________________ = R4 ONN
wherein R1 represents hydrogen, Cl_4alkyl, hydroxy-C2_4alky1, C1-3alkoxy-C2-4alkyl, Ci-3alkylcarbonyl-C1_4alkyl or C1_3alkyl(C1_3alkyl)amino-C2_4alkyl;
R2 represents C1_4alkyl, hydroxy-C2-4.a1ky1, C1_4alkylcarbonyl-C1_4alkyl, C1_3alkoxy-C2-4alkyl, C1-3alkyl(C1-3alkyl)amino-C2-4alkyl or halo-C2_4a1ky1;
R3 represents C1_4alkyl, ally1 or Ci_3alkoxy-C2_4alkyl;
Date Recue/Date Received 2021-07-07 R4 represents Cl_4alkyl, hydroxy-C1-4alkyl, C1_3alkoxy-C1_4alkyl, amino-C1-4alkyl, 1-hy droxy-di-(C _3 alkyl)methyl, 1 -amino-di-(Ci_3 kyl)methy I, 1 -hy droxy-cy cl o-C3-6 alkyl, 1-amino-cyclo-C3_6a1ky1, 1 -(hy droxy-C 1_3alkyl)-cycloC3_6 alkyl, C 1-heterocyclyl-Cl_3alkyl, aryl or heteroaryl;
with the proviso that if R2 is ethyl, R3 is methyl and R4 is 1-hydroxy-ethyl, then R1 is not a hydrogen;
with the proviso that if substituent R3 is at purine N(7) atom the dotted line between N(7) and C(8) represents no bond, and the dotted line between C(8) and N(9) represents chemical bond;
and with the proviso that if substituent R3 is at purine N(9) atom the dotted line between N(7) and C(8) represents chemical bond, and the dotted line between C(8) and N(9) represents no bond;
wherein the term "heterocycly1" represents saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heterocycly1 is one of azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl;
the term "aryl" represents phenyl or phenyl substituted by one or more substituents selected independently from halogen, cyano, C 1-4 al koxy carbonyl. N-C 1-4alkylaminocarbonyl, N,N-di-(Cl_3alkyl)aminocarbonyl, CH2OH, trifluoromethyl, CI_ 4alky1, allyl, C2_4alkynyl, Ci_4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alkoxy, hydroxy-Ci_4alkyl, Ci_3alkoxy-C1_4alky1, Ci_3alkoxy-C2_4alkoxy, 3 alkyl)amino, di-(Ci_3alkyl)amino-C 1-3 alkyl, di-(C1-3alkyl)amino-C2_4alkoxy, Ci_4alkylsulfonylamino and C1-4alky1-aminosulfonyl;
the term "heteroaryl" represents an aromatic 5 or 6 membered ring comprising one to three heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl is unsubstituted or is substituted by one or more substituents selected independently from halogen, cyano, trifluoromethyl, C1_4alkyl, C1_4alk0xy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alk0xy, Ci_3alkoxy-C1_4alkyl, cyclo-C3_6alkylamino and di-(C1_3alkyl)amino;
Date Recue/Date Received 2021-07-07 and its optical isomers, and pharmaceutically acceptable acid and base addition salts and hydrates and solvates thereof with the proviso that 8-(3-hydroxyprop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione is excluded;
comprising reaction of a compound of Formula II:
o ' C)NN
with a compound of Formula III:
¨ ____________________________________ R4 in the presence of base in an appropriate solvent, in the presence of CuI and palladium catalyst, or palladium catalyst generated in situ, to yield a compound of Formula I, which is convertible into an optical isomer, pharmaceutically-acceptable salt, hydrate or solvate.
R1 it N/R3 -W
j l ___________________________________ = R4 ONN
wherein R1 represents hydrogen, Cl_4alkyl, hydroxy-C2_4alky1, C1-3alkoxy-C2-4alkyl, Ci-3alkylcarbonyl-C1_4alkyl or C1_3alkyl(C1_3alkyl)amino-C2_4alkyl;
R2 represents C1_4alkyl, hydroxy-C2-4.a1ky1, C1_4alkylcarbonyl-C1_4alkyl, C1_3alkoxy-C2-4alkyl, C1-3alkyl(C1-3alkyl)amino-C2-4alkyl or halo-C2_4a1ky1;
R3 represents C1_4alkyl, ally1 or Ci_3alkoxy-C2_4alkyl;
Date Recue/Date Received 2021-07-07 R4 represents Cl_4alkyl, hydroxy-C1-4alkyl, C1_3alkoxy-C1_4alkyl, amino-C1-4alkyl, 1-hy droxy-di-(C _3 alkyl)methyl, 1 -amino-di-(Ci_3 kyl)methy I, 1 -hy droxy-cy cl o-C3-6 alkyl, 1-amino-cyclo-C3_6a1ky1, 1 -(hy droxy-C 1_3alkyl)-cycloC3_6 alkyl, C 1-heterocyclyl-Cl_3alkyl, aryl or heteroaryl;
with the proviso that if R2 is ethyl, R3 is methyl and R4 is 1-hydroxy-ethyl, then R1 is not a hydrogen;
with the proviso that if substituent R3 is at purine N(7) atom the dotted line between N(7) and C(8) represents no bond, and the dotted line between C(8) and N(9) represents chemical bond;
and with the proviso that if substituent R3 is at purine N(9) atom the dotted line between N(7) and C(8) represents chemical bond, and the dotted line between C(8) and N(9) represents no bond;
wherein the term "heterocycly1" represents saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heterocycly1 is one of azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl;
the term "aryl" represents phenyl or phenyl substituted by one or more substituents selected independently from halogen, cyano, C 1-4 al koxy carbonyl. N-C 1-4alkylaminocarbonyl, N,N-di-(Cl_3alkyl)aminocarbonyl, CH2OH, trifluoromethyl, CI_ 4alky1, allyl, C2_4alkynyl, Ci_4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alkoxy, hydroxy-Ci_4alkyl, Ci_3alkoxy-C1_4alky1, Ci_3alkoxy-C2_4alkoxy, 3 alkyl)amino, di-(Ci_3alkyl)amino-C 1-3 alkyl, di-(C1-3alkyl)amino-C2_4alkoxy, Ci_4alkylsulfonylamino and C1-4alky1-aminosulfonyl;
the term "heteroaryl" represents an aromatic 5 or 6 membered ring comprising one to three heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl is unsubstituted or is substituted by one or more substituents selected independently from halogen, cyano, trifluoromethyl, C1_4alkyl, C1_4alk0xy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alk0xy, Ci_3alkoxy-C1_4alkyl, cyclo-C3_6alkylamino and di-(C1_3alkyl)amino;
Date Recue/Date Received 2021-07-07 and its optical isomers, and pharmaceutically acceptable acid and base addition salts and hydrates and solvates thereof with the proviso that 8-(3-hydroxyprop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione is excluded;
comprising reaction of a compound of Formula II:
o ' C)NN
with a compound of Formula III:
¨ ____________________________________ R4 in the presence of base in an appropriate solvent, in the presence of CuI and palladium catalyst, or palladium catalyst generated in situ, to yield a compound of Formula I, which is convertible into an optical isomer, pharmaceutically-acceptable salt, hydrate or solvate.
1 1. The process of claim 10, wherein the solvent is selected from diisopropylethylamine (DIEA) in 2,5-dimethylfuran (DMF), N-methy1-2-pyrrolidone (NMP), dimethylacetamide (DMAC) and ethyl acetate (Et0Ac).
12. The process of claim 10 or 1 1, wherein the palladium catalyst is Pd(PPh3)4.
Date Recue/Date Received 2021-07-07
Date Recue/Date Received 2021-07-07
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/LV2015/000001 WO2016159745A1 (en) | 2015-03-27 | 2015-03-27 | Ethynylxanthines, preparation and use for cancer treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2989161A1 CA2989161A1 (en) | 2016-10-06 |
CA2989161C true CA2989161C (en) | 2022-03-01 |
Family
ID=52815227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2989161A Active CA2989161C (en) | 2015-03-27 | 2015-03-27 | Ethynylxanthines, preparation and use for cancer treatment |
Country Status (3)
Country | Link |
---|---|
CA (1) | CA2989161C (en) |
GB (1) | GB2553684B (en) |
WO (1) | WO2016159745A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2166948C1 (en) | 2000-05-29 | 2001-05-20 | Центральный научно-исследовательский рентгенорадиологический институт | Method for treating gliomae aggravated with epileptic syndrome |
EP1939197A1 (en) * | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
KR101610005B1 (en) * | 2007-08-17 | 2016-04-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Purin derivatives for use in the treatment of FAB-related diseases |
WO2011005871A1 (en) * | 2009-07-07 | 2011-01-13 | Pgxhealth, Llc | Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists |
CN107082782B (en) | 2013-03-15 | 2020-03-20 | 海德拉生物科学有限责任公司 | Substituted xanthines and methods of use thereof |
-
2015
- 2015-03-27 CA CA2989161A patent/CA2989161C/en active Active
- 2015-03-27 WO PCT/LV2015/000001 patent/WO2016159745A1/en active Application Filing
- 2015-03-27 GB GB1714548.3A patent/GB2553684B/en active Active
Also Published As
Publication number | Publication date |
---|---|
GB2553684A8 (en) | 2018-04-18 |
WO2016159745A1 (en) | 2016-10-06 |
CA2989161A1 (en) | 2016-10-06 |
GB2553684B (en) | 2020-06-03 |
GB2553684A (en) | 2018-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2698018C (en) | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | |
TW201718592A (en) | Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof | |
KR20180042368A (en) | A condensed pyrimidine compound or a salt thereof | |
CN104169283A (en) | Fused tetra or penta-cyclic pyridophthalazinones as PARP inhibitors | |
KR20060120393A (en) | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | |
CN101248050A (en) | Organic compounds | |
JP2008546653A (en) | N2-quinoline or isoquinoline substituted purine derivatives, process for producing the same and uses thereof | |
CA2604284A1 (en) | Protein kinase inhibitors | |
CN110167941A (en) | Substituted fused heteroaryl compounds are as kinase inhibitor and its application | |
JP2022518552A (en) | PDE9 inhibitor and its uses | |
JPS6225670B2 (en) | ||
JP2023145547A (en) | Cd73 inhibitor, preparation method therefor and application thereof | |
CN104557913B (en) | Pyridopyrimidine compounds as well as preparation method and application thereof | |
JP2015533778A (en) | Novel phenyl-pyridine / pyrazine amide for the treatment of cancer | |
El-Gamal et al. | Diarylureas and diarylamides with pyrrolo [2, 3-d] pyrimidine scaffold as broad-spectrum anticancer agents | |
CN108218874B (en) | Phosphodiesterase inhibitor and application thereof | |
WO2022007841A1 (en) | Egfr inhibitor, preparation method therefor, and pharmaceutical application thereof | |
CA2989161C (en) | Ethynylxanthines, preparation and use for cancer treatment | |
Guillonneau et al. | Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues | |
ES2896938T3 (en) | GSK-3 inhibitors | |
CA3135449A1 (en) | Triazolopyrimidines based on thymine nucleobase and methods for producing them | |
EP3098222B1 (en) | Fused acridine derivative and pharmaceutical composition, preparation method and use thereof | |
WO2016159747A1 (en) | Ethynylxanthines, preparation and use as calcium ion channel modulators | |
PL225349B1 (en) | 2',3'-dideoxy-5-fluorouridine derivatives with cytotoxic effect, their preparation and use | |
WO2016159746A1 (en) | Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200319 |